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Adult-type hypolactasia (primary lactose malabsorption), is the most common enzyme 
deficiency in humans, and present in majority of the world’s population. In Finland 
18% of the population have adult-type hypolactasia, and majority of them have 
symptoms (lactose intolerance) weekly. Adult-type hypolactasia has been shown to 
explain approximately one third of unspecific abdominal complaints. Adult-type 
hypolactasia is genetically determined and manifests during childhood when lactase 
activity declines to about 10-15% of the activity at birth. Adult-type hypolactasia is a 
common phenomenon for all sucklings. A pup is weaned from milk when it can 
manage without its mother’s milk, and lactase enzyme activity disappears from its 
intestine. 
 
A mutation that allows the persistence of lactase activity in the intestine occurred in 
man thousands of years ago. Our research group identified a genetic variation 
associated with adult-type hypolactasia, a one base polymorphism C>T-13910 year in 
2002. This polymorphism is located approximately 14 kilobases from the starting 
codon of the lactase-phlorizin hydrolase (LPH) gene, in intron 13 of the 
minichromosome maintenance 6 (MCM6) gene in chromosome 2q21-22. The variant 
is inherited recessively so that the C-13910 allele in a homozygous form (the C/C-13910 
genotype) is always associated with adult-type hypolactasia and the T-13910 allele (C/T-
13910 and T/T-13910 genotypes) with persistence of lactase activity. The C/T-13910 
polymorphism has been shown to be associated to the regulation of lactase enzyme 
activity at the transcriptional level. 
 
In this thesis, the timing and mechanism of decline of lactase enzyme activity during 
development was studied using the C/T-13910 variant associated with adult-type 
hypolactasia as a molecular marker. We observed that the C/C-13910 genotype 
associated with low lactase activity in all children aged > 12 years, despite their 
ethnicities. Lactase activity declined in Finnish children at an age of five to 12 years, 
in other Caucasians between three to six years and in children of African origin before 
the age of eight years. The sensitivity of the genetic test of adult-type hypolactasia in 
those aged > 12 years was 93% and the specificity 100%. In addition, we noticed that 
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the relative expression of lactase mRNA from the C-13910 and T-13910 alleles was equal 
in children up to four years of age. At ages between four and five years, the 
expression of lactase mRNA from the C-13910 allele began to decline in comparison to 
the T-13910 allele. In children aged > six years, the lactase mRNA expression from the 
C-13910 allele had declined to < 20% of that from the T-13910 allele. Thus, we showed 
that the relative expression of lactase mRNA from the C-13910 allele associated with 
adult-type hypolactasia declines during development and associates with the decline 
of lactase enzyme activity in subjects with the homozygous C/C-13910 genotype. 
 
In this work we also studied the relation of milk consumption and the milk-related 
abdominal complaints to the C/T-13910 genotypes associated with lactase 
persistence/non-persistence. We noticed that children and adults with the C/C-13910 
genotype associated with low lactase activity consumed significantly less dairy 
products compared to those with the C/T-13910 or T/T-13910 genotypes. Flatulence was 
the only of the classic symptoms of lactose intolerance that subjects with genotype 
C/C-13910 reported significantly more often than those with the C/T-13910 or T/T-13910 
genotypes. There was no association between cow’s milk allergy and adult-type 
hypolactasia.  
 
Furthermore, in this study we examined the association of adult-type hypolactasia and 
colorectal carcinoma. Our results showed a significant association between the C/C-
13910 genotype associated with low lactase activity and an increased risk of colorectal 
carcinoma. Any association between the age of the subjects, site, histology or degree 
of the tumor could not, however, be detected. No association between the C/C-13910 
genotype and colorectal carcinoma was seen in British and Spanish populations. 
Further studies are needed to clarify the role of dairy products in colorectal carcinoma 













Primaari maitosokerin eli laktoosin imeytymishäiriö on ihmisen yleisin 
entsyyminpuutos, ja sitä esiintyy suurimmalla osalla maapallon väestöstä. Suomessa 
18%:lla väestöstä on laktoosin imeytymishäiriö ja heistä enemmistö oireilee viikottain 
(laktoosi-intoleranssi). Laktoosin imeytymishäiriön on todettu selittävän noin 
kolmasosan epämääräisistä vatsavaivoista. Laktaasi-entsyymin aktiivisuuden 
aleneminen lapsuuden aikana suolen limakalvolla 10-15%:iin syntymähetkellä 
tavattavasta aktiivisuudesta on perinnöllisesti määräytynyt ominaisuus. Laktoosin 
imeytymishäiriö on kaikille nisäkkäille tyypillinen ilmiö.   Pennun tullessa toimeen 
ilman emon maitoa, on tarkoituksenmukaista vieroittaa pentu rinnasta ja laktaasi-
entsyymin aktiivisuus häviää imeväisen suolistosta.  
 
Ihmiselle on vuosituhansia sitten tapahtunut mutaatio, joka sallii laktaasin 
aktiivisuuden säilymisen suolessa. Tutkimusryhmämme tunnisti laktoosin 
imeytymishäiriöön liittyvän geenimuutoksen, yhden emäksen polymorfian C>T -13910 
vuonna 2002. Muutos sijaitsee n. 14 kiloemäksen päässä lactase-phlorizin hydrolase 
(LPH) -geenin aloituskodonista minichromosome maintenance 6 (MCM6) -geenin 
intronissa 13 kromosomissa 2q21-22. Kyseinen muutos osallistuu laktaasin säätelyyn 
transkriptiotasolla. Se periytyy peittyvästi siten, että C/C-13910 -genotyyppi liittyy aina 
laktoosin imeytymishäiriöön ja C/T-13910 tai T/T-13910 -genotyypit laktoosin sietoon.  
 
Väitöskirjatyössäni tutkin normaaliin kehitykseen kuuluvan laktaasi-entsyymin 
aktiivisuuden laskun yhteyttä äskettäin tunnistettuun MCM6 -geenin intronissa 
sijaitsevaan C/T-13910 -emäsmuutokseen sekä laktaasi-aktiivisuuden muutoksen 
mekanismia lapsuusiällä. Töissämme totesimme C/C-13910 -genotyypin assosioituvan 
matalaan laktaasi-aktiivisuuteen kaikilla yli 12-vuotiailla lapsilla etnisyydestä 
riippumatta. Suomalaislapsilla laktaasin aktiivisuus aleni viiden-12 vuoden iässä, 
muilla valkoisen rodun edustajilla kolmesta kuuteen -vuotiaina ja afrikkalaisilla ennen 
kahdeksan vuoden ikää. Laktoosin imeytymishäiriön geenitestin sensitiivisyys oli 
93% ja spesifisyys 100% yli 12-vuotiailla. Totesimme myös, että suhteellisesti yhtä 
paljon laktaasi mRNA:ta tuotetaan sekä C-13910 että T-13910 -alleelista lapsilla neljän 
vuoden ikään saakka. Neljän ja viiden ikävuoden välillä laktaasi-mRNA:n tuotto C-
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13910 -alleelista alkoi laskea T-13910 -alleeliin verrattuna, ja yli kuusi-vuotiailla se oli 
vähentynyt < 20%:iin T-13910 -alleelin ekspressiosta. Näin ollen, osoitimme laktoosin 
imeytymishäiriöön assosioituvan C-13910 -alleelin ekspression vähenevän iän myötä ja 
osallistuvan kehityksen aikana tapahtuvan laktaasi-aktiivisuuden laskuun mRNA-
tasolla henkilöillä, joiden genotyyppi on homotsygootti C/C-13910.  
 
Tutkimuksessa selvitimme myös maidon käytön ja maidon aiheuttamien oireiden 
yhteyttä laktoosin imeytymishäiriön perintötekijätyyppeihin suomalaislapsilla ja -
aikuisilla. Totesimme sekä lasten että aikuisten, joilla on matalaan laktaasi-
aktiivisuuteen assosioituva C/C-13910 -genotyyppi, käyttävän merkitsevästi vähemmän 
maitotuotteita kuin genotyyppiryhmiin C/T-13910 ja T/T-13910 kuuluvat. Klassisista 
laktoosi-intoleranssin oireista vain ilmavaivat olivat merkitsevästi yleisempiä 
laktoosin imeytymishäiriöstä kärsivillä. Maitoallergian ja laktoosi-intoleranssin välillä 
emme todenneet yhteyttä.  
 
Lisäksi väitöskirjassani selvitimme onko laktoosin imeytymishäiriöllä ja sen 
mahdollisesti aiheuttamalla suolen ärsytyksellä yhteyttä paksunsuolensyövän syntyyn. 
Totesimme matalan laktaasi-aktiivisuuden määrittävän C/C-13910 genotyypin liittyvän 
suomalaisilla merkitsevästi kohonneeseen paksunsuolensyövän riskiin. C/C-13910 
genotyypin yliesiintyminen ei liittynyt ikään, kasvaimen paikkaan, histologiaan tai 
syövän asteeseen. Englantilaisilla ja espanjalaisilla emme todenneet yhteyttä 
paksunsuolensyövän ja C/C-13910 -genotyypin osalta. Lisätutkimuksissa pyrimme 
selvittämään maitotuotteiden käytön merkitystä paksunsuolensyövässä eri laktoosin 



















Milk is an excellent source of the nutrients needed for a healthy diet. It is especially 
important for newborns, as it is their primary energy source. The milk sugar, lactose, 
is a disaccharide composed of galactose and glucose units. Lactose cannot be utilized 
as such but needs first to be hydrolyzed by the enzyme lactase-phlorizin hydrolase 
(LPH) in the brush-border membrane of the small intestinal epithelium to its 
constituent monosaccharides, which are quickly absorbed (1, 2). Lactase has a unique 
pattern of activity in animals: its level in mammals increases shortly before birth and 
remains high until weaning. After that, lactase is downregulated and its activity 
declines to the very low levels seen in adult mammals (adult-type hypolactasia). In 
humans, a considerable number of individuals maintain high levels of intestinal 
lactase activity throughout adulthood, whereas in the rest lactase activity declines to 
about one-tenth of the activity of infants (2).  
 
The majority of subjects with low lactase activity experience symptoms of lactose 
intolerance such as flatulence, bloating and diarrhea after consumption of lactose 
containing milk products; the symptoms, however, vary widely among individuals 
(3). Although the symptoms are most often mild, adult-type hypolactasia has a 
significant role in unspecific abdominal complaints in populations with high 
consumption of dairy products. The diagnosis of adult-type hypolactasia is usually 
based on the lactose tolerance test (LTT), which measures the increase in blood 
glucose after an oral lactose load (4). The incidence of false-positive results in LTT, 
however, is high; in children it may even be as high as 30% (5). The assay of mucosal 
disaccharidases directly from an intestinal biopsy sample is the reference method, 
although it is unsuitable for everyday clinical practice (4, 6).  
 
Adult-type hypolactasia, i.e., a low lactase activity in the intestine was in 1973 shown 
to be inherited as an autosomal recessive trait (7). In 2002, a single-nucleotide 
polymorphism (SNP), C to T change 13,910 basepairs (bp) from the 5’end of lactase 
(LCT) gene trait was identified to be associated with the lactase persistence/non-
persistence trait. The homozygous C/C-13910 genotype completely associated with low 
lactase activity in the small intestine (8). This finding has allowed functional studies 
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of the variant in regulation of the LCT gene, population genetic studies as well as 
studies on the association of the variant in various diseases to be carried out. Here the 
studies were focused on the timing and mechanism of downregulation of lactase 
activity in the intestine of children at various ages and ethnicities at the protein, DNA 
and RNA levels (I, II). Moreover, this study has assessed the applicability of the 
genetic test of the C/T-13910 variant as a screening method for adult-type hypolactasia 
as a cause of gastrointestinal symptoms in children and in Finnish adults (I, III, IV). 
The consumption of milk products, and the prevalence of various gastrointestinal 
symptoms have been studied in Finnish children and adults, and the findings have 
been related to the C/T-13910 genotype of the subjects (I, III, IV). Finally, the 
identification of the C/T-13910 variant has allowed us for the first time to conduct a 
large-scale study on the role of lactase activity as a risk factor on the development of 


























REVIEW OF THE LITERATURE 
 
1. LACTOSE AND ITS METABOLISM  
 
Lactose, the main carbohydrate of milk, is synthesized in the mammary gland by 
participation of β1,4 galactosyl transferase (EC 2.4.1.22) and α-lactalbumin (9-11). 
The concentration of lactose in milk varies between species (12). Cow’s milk contains 
4.7 g lactose in 100 ml of milk, and human milk, in which the lactose content is 
highest of all mammals, 7.0 g in 100 ml (13). Lactose is the primary energy source of 
newborns. Lactose has several applications in the food industry because of its 
physiological properties: it provides good texture and binds water as well as color. It 
is less than half as sweet as glucose (14).  
 
Lactose is a disaccharide composed of galactose and glucose units joined by a β(1-4) 
linkage.  After ingestion of lactose, it is hydrolyzed into glucose and galactose 
monosaccharides by lactase-phlorizin hydrolase (LPH) enzyme in the brush-border 
membrane of the small intestinal epithelium. These monosaccharides are transported 
through the intestinal epithelium using the sodium-dependent glucose transporter 1 
(SGLT1) (15). Glucose enters the body glucose pool directly, whereas galactose is 
first metabolized to glucose by UDP-galactose 4-epimerase. This occurs mainly in the 
liver and is extremely efficient (16). 
 
In subjects with low levels of lactase activity, most of lactose remains unhydrolyzed 
in the jejunum. The osmotic load of the unhydrolyzed lactose in the small intestine 
results in an influx of water into the lumen, which contributes to rapid intestinal 
transit (Figure 1). In the colon, microbes metabolize lactose into various gases and 
short-chain fatty acids (SCFAs). Carbon dioxide, hydrogen and methane are the 
principal gases formed and in excess they cause abdominal distension, bloating and 
flatulence. The gases diffuse into the blood stream and are exhaled through the lungs 
or excreted as flatus (1). The SCFAs formed include among others acetic, butyric, 
propionic, succinic, lactic and formic acids (17). The SCFAs are rapidly absorbed 
from the intestine. Acetic acid, which represents up to 50% of the total SCFAs is 
finally metabolized in the peripheral tissues, whereas butyric and propionic acids 
undergo final metabolism in the liver. The individual differences in the composition 
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of intestinal microbiota have an effect on the rate of lactose fermentation and thus 
account for the different tolerance to lactose in subjects with adult-type hypolactasia 
(1). 
 
Figure 1. Metabolism of lactose in subjects with high and low lactase activities. 





2. LACTASE-PHLORIZIN HYDROLASE (LPH) 
 
 
Lactase-phlorizin hydrolase (LPH) was in 1906 shown to be present in the intestine of 
pups (18, 19). After half a century, entire curves of lactase enzymatic activity during 
development had been constructed for several animal species (20, 21). Holzel, in 
1959, was the first to describe children with intolerance to lactose (22).  Adult-type 
hypolactasia was reported by Italian and Swedish groups in 1963 (23, 24). The gene 
encoding lactase-phlorizin hydrolase was localized to chromosome 2q in year 1988 
(25), and more specifically to 2q21 in 1993 (26).  The complete primary structure of 
human LPH was established in 1988 (27) and the complete intron-exon organization 
in 1991 (28). 
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2.1 Structure  
 
The human lactase-phlorizin hydrolase -gene (LCT) is about 55 kB in size and is 
composed of 17 exons (28). It encodes for lactase-phlorizin hydrolase (EC 3.2.1.23; 
3.2.1.62), which is a β-galactosidase present most abundantly in the proximal 
jejunum. LPH has two activities: lactase hydrolyses lactose to galactose and glucose, 
whereas phlorizin hydrolase splits aryl- and alkyl-β-glycosides to phlorizin and β-
glycosylceramides (2). In addition, the lactase activity cleaves cellobiose, cellotriose, 
cellotetrose and cellulose to a certain extent (29, 30). In spite of its two separate 
activities, LPH is synthesized as a single messenger RNA (mRNA) of 6247 bases 
(28), and translated as a pre-pro-polypeptide consisting of 1927 amino acids (aa) (27). 
There are four repeats in the LPH amino acid sequence, all homologous to a β-
glycosidase unit, indicating that the gene has undergone two rounds of partial gene 
duplications (27). Because the phlorizin hydrolase activity is found in all vertebrates 
so far studied, but lactase activity is confined to mammals, it is believed that phlorizin 
hydrolase is the phylogenetic progenitor of both catalytic activities in the LPH 
complex (27). The human pre-pro LPH comprises five domains: (1): a cleavable 
signal sequence of 19 aa, (2) a pro portion of 849 aa, including repeats I and II, (3) the 
mature enzyme containing both phlorizin hydrolase catalytic sites (repeat III) and 
lactase active site (repeat IV), (4) membrane-spanning hydrophobic segment serving 
as the membrane anchor, and (5) a cytosolic hydrophilic segment at the C-terminus 
(2, 27, 31, 32) (Figure 2a). 
 
2.2 Biosynthesis  
 
The cleavage of the 19 aa signal sequence of pre-pro-LPH to pro-LPH takes place in 
the endoplasmic reticulum (ER) and occurs during the process of translocation of the 
pro-LPH over the ER (33, 34) (Figure 2b I). The N-terminal sequences of pro-LPH 
are similar in human, rat and rabbit (2). The pro-LPH becomes N-glycosylated and 
forms homodimers in the ER (35, 36). The dimerization involves the C-terminal 
transmembrane domain and the cytoplasmic tail region (35). After that the pro-LPH is 
transported to the Golgi complex where it is complex- and O-glycosylated (37) 
(Figure 2b II). Glycosylation is needed both for enzymatic activity as well as for 
intracellular transport (37-40). The pro-sequence is cleaved off, in the trans-Golgi 
 15
 
complex or in a later compartment (41), in various steps by furin or a furin-like 
convertase before transport to the brush border membrane (34). This processing 
differs between the species studied, most likely due to the presence or absence of the 
furin and furin-like consensus sequences in the pro-LPH (2). The only function of the 
pro-sequence seems to be that it is needed for LPH to exit the ER, i.e. to pass the 
quality control of the secretory pathway (42-44). Lactase expressed in COS cells 
without its pro-sequence is retained in the ER (43, 44). The final proteolytic cleavage 
of LPH is carried out in the microvillus membrane by pancreatic trypsin (45) (Figure 
2b III). 
 


























2.3 Expression at organ and cellular levels 
 
Expression of LPH is restricted to the small intestine of all mammals investigated (29, 
36), making it a commonly used marker for differentiated enterocytes. In humans, the 
expression of lactase increases from the pylorus to the jejunum, with a maximum at 
25% of gut length, it decreases from 50-70% of the gut length and after that remains 
stable (46). The mature LPH enzyme is positioned at the crypt/villus junction and on 
the villus of the enterocytes. It is anchored to the brush border membrane by its C-
terminal transmembrane domain. Phlorizin hydrolase activity is more distal and 
lactase activity is closer to the membrane. The location of lactase at the tip of 
microvilli makes it most vulnerable to intestinal diseases which cause cell damage in 
comparison to the other disaccharidases, which are located deeper (14).  
 
2.4 Expression during development 
 
Lactase-phlorizin hydrolase is a critical enzyme for neonates that depend on their 
mother’s milk for nourishment. In most species, including the majority of the human 
population, the LPH activity diminishes when mother’s milk is not longer necessary 
for nutrition. In the human fetal small intestine LPH becomes expressed between 
gestational weeks 9 and 10 when the transition from undifferentiated endoderm to a 
columnar intestinal-type epithelium occurs (47). The expression of LPH is relatively 
low until approximately 24 weeks, with a gradual increase from then on until late 
gestation, after which a marked increase occurs around 32 weeks of gestation. The 
increased activity remains until early infancy, but decreases somewhat in the first year 
of life (48, 49). The obtained level of expression of LPH is then maintained during 
childhood (47).  
 
Depending on the population, at some point during childhood or adolescence, LPH 
activity declines to approximately 10% of the activity of childhood levels (lactase 
non-persistence, adult-type hypolactasia). This is the case for the majority of the 
world’s population, whereas in the rest, lactase activity persists throughout life 
(lactase persistence) (Figure 3). The age of the genetically determined decline of 
lactase activity has been difficult to study due to the difficulty in obtaining intestinal 
specimen from healthy children. However, in populations with high prevalences of 
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adult-type hypolactasia, the condition seems to manifest at an early age (50). In some 
Asian populations, where adult-type hypolactasia prevalence is as high as 100%, 
adult-type hypolactasia manifests as follows: in Thai children before two years (51), 
in Bangladesh before three years (52) and in Chinese children between three and eight 
years of age (53, 54). In African populations, lactase activity decreases in children 
beginning from three years of age (55) and in the majority (86%) of Somalian 
children lactase activity has been observed to be low (< 20 U/g protein) at ages > five 
years (56). In Peru (57) and Jamaica (58), 80% of the children were considered to be 
lactose maldigesters by the age of three years. In Israeli children manifestation was 
mostly between three and six years, but even at ages up to 12-16 years (59). In 
children of Caucasian origin, manifestation of lactose malabsorption (LM) seems to 
occur at a later age: in Greek children the prevalence of LM increases linearly 
between the ages of five and 12 years (60), and in the Finnish population between five 
and 20 years (61-63).  
 




2.5 Regulation of LPH expression 
 
The lactase (LCT) gene is regulated at several levels: 1) at the cellular level during 
differentiation of the enterocyte, 2) at the organ level for tissue specific and 




2.5.1 At the cellular level 
 
Lactase expression is patchy in the distal parts of the small intestine in rat (64) and 
rabbit (65) after weaning. In humans with adult-type hypolactasia, this phenomenon is 
observed both at the enzyme and mRNA levels (65, 66). This implies a complete turn-
off of lactase expression in the majority of enterocytes instead of a general 
downregulation of lactase expression in all enterocytes. Moreover, lactase mRNA is 
observed to be strictly localized in the cytoplasm below the apical membrane of the 
enterocyte, but the reason for the restricted localization is not understood (36, 67). 
 
 2.5.2 During development 
 
The downregulation of lactase activity during childhood in humans is commonly 
considered similar to the post-weaning decline of lactase expression in mammals, e.g. 
the baboon (36, 68). The developmental decline in lactase activity seems mainly to be 
regulated at the transcriptional level in humans (69-74), in rat (75, 76), pig (77) and 
sheep (78). However, regulation at posttranscriptional level, too, has been suggested 
in humans (73, 79-82) and in rat (83). Some lactase non-persistent subjects have high 
expression of lactase mRNA (79, 81).  In these rare subjects, the underlying factors 
may be posttranscriptional and posttranslational regulation causing mRNA 
degradation or failure of intracellular processing of the synthesized LPH enzyme, 
such as slow transport of the transcript, failure in maturation of the enzyme or failure 
to reach the membrane (81). 
 
Sequence alignment of the lactase promoter in human, pig, rabbit, mouse and rat 
shows a conserved region of 150 bp just upstream of the transcription initiation site 
(36). Several regulatory transcription factor -binding sites (cis-elements) have been 
identified in the promoter region of pigs (84-86), rats (87) and humans (88, 89). 
Moreover, numerous transcriptional regulators in pigs (84, 86, 90), rats (83, 87) and 
humans  (88, 89, 91-94), respectively, activating transcription from the LPH 
promoter, have been recognized. The pig 0.9 kb upstream sequence includes at least 
six cis-elements, of which two, CE-LPH1a and CE-LPH3, show 100% sequence 
similarity to human. Three other elements, CE-LPH1b, CE-LPH2c and CE-LPH4 are 
also well conserved between pig and human (86). An intestine-specific transcription 
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factor, Cdx-2, as well as another homeodomain protein, HOXC11 (91), interact with 
the LPH promoter through the TTTAC sequence of CE-LPH1a (94) and activate 
reporter gene transcription. HNF1α, a transcriptional activator, binds the CE-LPH2c 
element and when co-transfected with HOX11 produces 7-19-fold stimulation of 
transcription. A direct protein-protein interaction between Cdx2 and HNF1α leads to 
an increased level of gene activation (92). The regulator binding CE-LPH3, on the 
other hand, is a repressor that binds a member of the FREAC family (86). A GATA-
binding site element has been identified in rat to locate between –73 and –100 bp; 
GATA-4 and GATA-6 interact with this element and activate transcription from 
lactase promoter in intestinal cells (89). GATA-5 and HNF1α also show co-operative 
activation of LPH expression (94). In rat, HNF3β binds at three sites enhancing LPH 
expression (87). Interestingly, the binding capacities of nuclear factors for the CE-
LPH1 element and for HNF1α binding site in LPH promoter change during the post-
weaning period (84, 86, 92, 95). In pig, a 100 bp region around position –850 
upstream of the lactase gene bound with HNF-1α and an unidentified factor, has been 
observed to be necessary for high expression of lactase in Caco-2 cells (96). This 
sequence, however, has not been found in humans or rats.  Unfortunately, 
comparisons of studies on the distal regulatory elements from other mammals to 
humans is rather complicated due to the fact that the 5’- flanking region of the human 
LPH gene contains five inserted stretches of repetitive DNA (97) (Figure 4).  
 















3. LACTASE DEFICIENCIES 
 
3.1 Terminology  
 
Hypolactasia is term for a very low activity of lactase in the jejunal mucosa, whereas 
alactasia and lactase deficiency mean a total lack of lactase activity. Lactose 
malabsorption or lactose maldigestion imply a poor lactose digesting capacity. 
Congenital lactase deficiency (CLD) is the most severe form of lactase deficiency and 
manifests in neonates fed breast milk. Adult-type hypolactasia (lactase non-
persistence) is a genetically determined condition. It is the ancient phenotype and 
characterized by decline in lactase activity during childhood. Adult-type hypolactasia 
causes primary lactose malabsorption (98).  Secondary lactose malabsorption is 
caused by other reasons than genetically determined adult-type hypolactasia, such as 
microbial infections or celiac disease that damage the intestinal villi (99). Lactose 
intolerance refers to symptoms after lactose ingestion, and milk intolerance simply 
means gastrointestinal symptoms after milk ingestion (98) (Table 1). 
 


















Secondary lactose malabsorption 
Primary lactose malabsorption/ lactase 
non-persistence/ adult-type hypolactasia 
Congenital lactase deficiency 
Lactose malabsorption/ lactose 
maldigestion 
Alactasia/ lactase deficiency 
Hypolactasia 
symptoms from milk 
symptoms from lactose 
Caused by mucosal injury, reversible 
Manifests during normal development, 
irreversible 
Rare disease of newborns 
Poor lactose hydrolysing capacity 
Total lack of lactase activity 




3.2 Congenital lactase deficiency (CLD) 
 
Congenital lactase deficiency (CLD) is characterized by an almost total lack of lactase 
activity in the intestinal mucosa. CLD is a rare disorder and affects approximately 
1:60 000 newborns in Finland (100). It is considered to belong to the so-called 
Finnish disease heritage, that have been enriched in the Finnish population due to the 
founder effect and genetic drift (101-103). Single cases of CLD have been reported 
outside Finland (104). Congenital lactase deficiency manifests as a watery diarrhea 
during the first days of life of an infant fed lactose-containing milk. Despite their 
good appetite and absence of vomiting, the diarrhea and loss of nutrients is so 
comprehensive that at the time of diagnosis children with CLD usually weigh less 
than their birth weight and suffer from dehydration and acidosis (100). The lactase 
activity in jejunal biopsies is observed to range from 0 to 10 U/g protein (100, 105). 
On a lactose-free diet the children, though, grow and develop normally (100).  
 
3.2.1 Genetics of CLD 
 
CLD is inherited as an autosomal recessive trait (100). A genealogical study revealed 
that CLD is enriched in eastern and northern Finland. The gene locus of CLD was 
assigned to chromosome 2q21 in Finnish families. The analyses of ancient haplotypes 
and linkage disequilibrium initially restricted the CLD region to a locus >2 Mb 
upstream of the LPH gene (106). However, detailed analysis of the haplotypes in the 
region and sequencing of the LPH gene resulted in identification of five mutations in 
the coding region of the LPH gene. A nonsense mutation c.4170T→A (Y1390X), 
Finmajor, predicting an early truncation of the lactase gene, was found in 84% of the 
patients. The four other mutations were rare. Two of the mutations resulted in a 
predicted frameshift and premature truncation at S1666fsX1722 and S218fsX224, 
respectively, and the two other in amino acid substitutions Q268H and G1363S (105). 
The carrier frequency of the Finmajor mutation was observed to be 1:35 in central 







3.3 Adult-type hypolactasia 
 
Adult-type hypolactasia unlike CLD is not a disease but part of the normal 
development of mammals. At the time of weaning, the lactose content of food falls 
rapidly, and activity of lactase becomes unnecessary.  In humans, lactase activity 
declines during childhood to approximately 10% of the activity at birth. Lactase non-
persistence is indeed the more ancient phenotype in the human history, and those with 
high adult lactase activity carry the mutation (107). Subjects with lactase persistence 
are frequent in European populations and their descendents on other continents (108). 
 
3.3.1 Clinical features  
 
Hypolactasia, in most cases, leads to symptoms of lactose intolerance when a person 
with low lactase activity consumes lactose-containing food. The classic symptoms of 
lactose intolerance include abdominal bloating and pain, fullness, cramps, 
borborygmi, flatulence, loose stools and diarrhea (14, 109, 110). The former 
symptoms result from an increased motility of the intestine and an increased gas 
production due to bacterial fermentation of the unhydrolyzed lactose in the colon; a 
mechanism developed in order to conserve the nutritionally important calories.  Loose 
stools and diarrhea, on the other hand, are due to an osmotic effect caused by 
unhydrolyzed lactose, leading to an increased secretion of water and electrolytes into 
the intestinal lumen until osmotic equilibrium is reached (109, 111). An increase in 
peristalsis and the hyperemic and edematous mucosa has been observed in 
jejunoscopy on subjects with adult-type hypolactasia following a lactose challenge 
(112).  
 
The development of symptoms of lactose intolerance is individual. Interestingly, 
marked differences also exist at the population level. The severity of the symptoms 
has a correlation with the amount of lactose consumed, but also with the diet with 
which lactose is consumed, the rate of abdominal emptying, the small-intestinal 
transit time, individual sensitivity to the stretching of the intestinal wall as well as the 
degree of adaptation to lactose developed (14, 109, 110). Delayed gastric emptying 
has been observed to improve tolerance to lactose (113). Children are more prone to 
abdominal symptoms as well as loose, fluid stools because the passage of the lactose 
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content through small intestine and colon is normally more rapid. In adults diarrhea is 
often avoided, because the dietary load of lactose is smaller in relation to body 
weight, and there is more time for reabsorption within the colon (114). The 
composition of the colonic microbiota probably has a marked effect, although the 
factors affecting it are unknown. In hypolactasic subjects who tolerate lactose well 
large intestines densely colonized with anaerobic bacteria such as those of the 
Bacteroides group have been observed (115). β-galactosidase is the bacterial enzyme, 
which catalyzes the first step of lactose fermentation in the colon. β-galactosidase 
activity may vary 4-fold among the lactose-fermenting bacteria (1). A recent study 
tackled the role of colonic microbiota in lactose intolerance symptomatology by 
studying the amount and composition of the bacteria with β-galactosidase activity in 
subjects with primary low lactase activity and their controls. There was, however, no 
difference either in the percentage or the composition of the bacteria with β-
galactosidase activity or β-galactosidase activity in feces between the tolerant and the 
intolerant groups (116). 
 
It seems obvious that genetic factors have more or less effect on the clinical outcome 
of lactose intolerance. In some families with diagnosis of lactose malabsorption, 
intolerance does not seem to occur at all or the symptoms are very mild, whereas in 
other families an evident accumulation of the most symptomatic forms of lactose 
intolerance is observed (109, 117).  Lactose intolerance may also present among some 
lactose absorbers after the ingestion of lactose, although the reason for this is unclear. 
It is probable that at least in some of these subjects some other underlying 
gastrointestinal disturbance, such as irritable bowel syndrome, is misattributed to 
lactose intolerance (14, 109, 114, 118).  
 
3.3.2 Management  
 
Lactase is a non-adaptable enzyme (119), thus the basis of the treatment of lactose 
intolerance is to reduce the amount of lactose in the diet; the degree of the restriction 
depends on the individual’s tolerance (120). The majority of adults with lactose 
malabsorption tolerate 100 ml of milk, equaling about five grams of lactose without 
symptoms (121-123). Interestingly, lactose-free milk has been shown to induce 
symptoms in as many lactose malabsorbers as a milk containing seven grams of 
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lactose (123). Furthermore, chocolate with varying amounts (two-12 g) of lactose was 
equally well tolerated by subjects with self-reported lactose malabsorption (124),  
suggesting that small amounts of lactose do not play a significant role in the 
symptomatology of lactose intolerance. A cup of 200-250 ml of milk causes 
symptoms in 30-75% of the subjects, depending on the study population (122, 125-
128). The consumption of 500 ml of milk or 50g of lactose, such as in a clinical 
tolerance test, causes symptoms in 80-100% of subjects with lactose malabsorption 
(122, 127, 129).  
 
Lactose is better tolerated when it is consumed with some other food or when it is 
divided between several meals (130). Lactose content varies between different dairy 
products, and for example cheese which has a low lactose content is well tolerated, 
meaning that not all milk products need to be restricted in the diet. In some countries, 
such as Finland, low-lactose products in which lactose has been pre-hydrolyzed, as 
well as lactose-free milk in which lactose is removed from the milk with 
chromatographic separation, are available. Furthermore, the absorption of lactose can 
be facilitated by exogenous lactase preparations (121).  
 
3.3.3 Nutritional consequences  
 
Milk has a high content of protein and calcium. The main nutritional consequences of 
lactose intolerance seem to be due to decreased intake of calcium resulting from 
avoidance of dairy products. Both children (131) and adults (132-135) avoiding dairy 
products have been shown to have lower dietary intake of calcium and impaired bone 
health. Moreover, several studies have shown an increased incidence of adult-type 
hypolactasia, although diagnosed with methods of varying sensitivity and specificity, 
among subjects with osteoporosis or bone fractures (136-139).  
 
Apart from the decreased absorption of lactose, the effects of lactose maldigestion on 
the absorption of other nutrients seem minimal. Several studies have assessed the 
absorption of calcium from milk in lactase persistent and deficient subjects, but the 
results have remained controversial (140-144). The infusion-aspiration technique with 
phenolsulphthalein (PSP), that is a nonabsorbable ileal recovery marker, has been 
used to quantify flow through the terminal ileum after a test meal of milk in subjects 
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with high lactase activity and those with adult-type hypolactasia (140). After whole 
milk, more protein, calcium, magnesium and phosphorus were recovered from the 
ileum in lactase deficient subjects. The authors, however, concluded that as the age 
and sex of the controls and subjects differed greatly, and as the status of vitamin D 
metabolism was not monitored, the direct comparison of the groups was not 
appropriate (140). Using the double-isotope technique, with a test meal of lactose and 
calcium in water, Cochet et al, concluded that the effect of lactose on calcium 
absorption is dependent on intestinal lactase activity (141). In their study calcium 
absorption was increased in subjects with normal lactase activity, when accompanied 
with lactose, whereas in subjects with adult-type hypolactasia lactose decreased 
calcium absorption (141). Zitterman et al., on the other hand, used the stable-
strontium test, and observed that lactose does not have a beneficial effect on calcium 
bioavailability in lactose tolerant subjects (142). Tremaine et al., applying the double-
isotope technique showed that malabsorption of lactose does not affect calcium 
absorption. In fact, the mean calcium absorption from both lactose-hydrolyzed and 
unhydrolyzed milk was significantly greater in subjects with adult-type hypolactasia 
in comparison to the lactase persistent subjects (143). This was, however, expected to 
be a consequence of a lower dietary calcium intake in the lactase malabsorbers, since 
decreased calcium intake is known to cause a compensatory increase in calcium 
absorption (143). 
 
3.3.4 Diagnosis  
 
Although response to withdrawal of lactose from the diet should be excellent in 
lactose intolerance, the diagnosis of adult-type hypolactasia based solely on 
symptoms is inaccurate (4, 145). Due to the considerable proportion of adult-type 
hypolactasia as a cause of unspecific abdominal complaints and its high prevalence 
worldwide, several laboratory methods have been developed for diagnostic purposes. 
The diagnostic methods are direct, as in measurement of the disaccharidase activities 
in intestinal biopsies or indirect, such as in the oral tolerance test or the breath 






3.3.4.1 Measurement of disaccharidase activities  
 
Measurement of intestinal disaccharidase activities is the golden standard for 
diagnostics of adult-type hypolactasia, however, it is not suitable for routine 
diagnostics. It is to be noted that the disaccharidase values are affected by several 
factors, including age and ethnicity of the subjects as well as the biopsy site. If the 
intestinal mucosa is damaged all disaccharidase activities diminish leading to 
secondary disaccharidase deficiency, which, however, disappears when small-
intestinal changes heal up (2).  
 
There is an abrupt gradient of disachharidase activity in the proximal duodenum (146, 
147), thus the standardization of the biopsy site to obtain reproducible duodenal 
biopsies is essential. The duodenal biopsies should be obtained from a relatively fixed 
site approximately 10-20 cm distal to the ligament of Treitz (4) in order to avoid  
biopsies from too proximal parts of the duodenum that show overall low activities of 
all disaccharidases. The biopsy technique as such has no effect on the enzyme activity 
(148). 
 
In Finnish subjects, the values of disaccharidase activities regarded as normal range 
from 20-140 U/g protein for lactase, 40-250 U/g protein for sucrase and 150-700 U/g 
protein for maltase, with a lactase/sucrase ratio > 0.3 (Reference intervals of the 
Laboratory of Hospital for Children and Adolescents, University of Helsinki).  
 
3.3.4.2 Lactose tolerance test (LTT)  
 
The lactose tolerance test is based on the determination of the increase in blood 
glucose in blood samples taken at intervals of 15 to 30 min up to two hours after an 
oral load of 50 g of lactose. A rise in blood glucose > 1.7 mmol/l is indicative of 
normolactasia and that of < 1.1 mmol/l for hypolactasia. Symptoms after the test also 
need to be recorded (4), and symptoms combined with a marginal rise of blood 
glucose indicate hypolactasia. 
 
It has been estimated using assay of disaccharidases as a reference method that the 
specificity of LTT is 77-96% and sensitivity 76-94% (4). LTT has been observed to 
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result in false positive results in approximately 30% of children tested (5). Also, the 
test is not reliable in diabetics since abnormal blood glucose levels might affect the 
result (149). Delayed gastric emptying has been observed to cause false positive 
results, too (5, 150). 
 
3.3.4.3 The lactose tolerance test with ethanol (LTTE) 
 
In the lactose tolerance test with ethanol (LTTE), blood galactose concentration is 
determined in one single blood sample taken 40 min after an oral lactose load. 
Ingestion of ethanol is used to inhibit the conversion reaction of galactose to glucose 
in the liver, which otherwise would occur rapidly after lactose ingestion. Blood 
galactose concentration of < 0.3 mmol/l at 40 min after lactose and ethanol ingestion 
indicates hypolactasia. The measurement of galactose instead of glucose makes the 
test more specific (4, 61, 151). The specificity of the test has been evaluated to range 
from 96% to 100% and sensitivity from 81% to 100% (4). Furthermore, the test is 
suitable for diabetics as well, and is less vulnerable to changes in gastric emptying 
rates (4). It is however not allowed to use the test on children.  
 
3.3.4.4 Breath hydrogen determination (BHT) 
 
The breath hydrogen test is based on the determination of exhaled hydrogen produced 
by the bacterial flora in the colon after an oral lactose load. The samples of hydrogen, 
taken at intervals of 15 to 60 min for two to six hours, are collected, and the change in 
hydrogen concentration in the expired air determined by gas chromatography. In 
hypolactasia hydrogen concentration increases > 0.3 ml/min over the baseline (4).  
 
The specificity of BHT varies between 89-100% and sensitivity ranges from 69-100% 
(4). Prior exercise (152), use of acetylsalicylic acid (153) or antibiotics (154), and 
smoking (155) will increase the rise in hydrogen concentration. In addition, some 
subjects may be colonized with bacteria that are incapable of producing hydrogen 
(156), whereas in some cases colonic bacteria may consume hydrogen (154) and 
produce methane (CH4) from it (157). The possible presence of methanogenic bacteria 




Table 2. The specificity and sensitivity of the diagnostic methods of adult-type 




93% 100% Genetic test (C/T-13910)* 
69-100% 89-100% BHT 
81-100% 96-100% LTTE 
76-94% 77-96% LTT 









   *) In Finnish subjects >12 years of age 
 
3.3.5 Role in unspecific abdominal complaints 
 
Unspecific abdominal complaints cause concern for a considerable percentage of both 
children and adults and are frequent causes for visits to primary health care centers 
(158-162). Irritable bowel syndrome (IBS) is a common functional gastrointestinal 
disorder, with symptoms very reminiscence of those for adult-type hypolactasia, but 
not explained by structural or biochemical abnormalities (118).  
 
Numerous studies have explored the role of adult-type hypolactasia as a cause of 
abdominal complaints. In Finnish and Estonian studies hypolactasia was observed to 
occur significantly more often among adults with unspecific abdominal complaints 
than in the general population (117, 163). In another Finnish study after testing with 
LTTE, the percentage of subjects with adult-type hypolactasia among the IBS -group, 
however, was the same as for the whole study group (118). Adult-type hypolactasia 
seems to associate more often with IBS, the greater the frequency of lactase non-
persistence is in the population. This is illustrated in two Danish studies: among 
Danish patients with IBS, LM was diagnosed in 20% of the study subjects (164), 
whereas in immigrant workers with IBS, originally from areas with high prevalences 
of adult-type hypolactasia, the frequency of LM was as high as 85% (165). Although 
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the number of study subjects in the latter was low, it illustrates a common problem 
among immigrants in Northern European countries: when the traditional diet is 
changed to a lactose-containing diet of the new country, gastrointestinal symptoms 
appear. Not only children but also adults may simply be unaware of intolerance to 
lactose (127, 166), further complicated by the nature of the condition: the symptoms 
are non-specific, vary in frequency, and the discomfort occurs only some time after 
lactose consumption. On the other hand, in populations with general awareness of 
lactose intolerance such as Finland, self-reported, subjective lactose intolerance has 
been observed to strongly relate to IBS (118). Nevertheless, it should always be kept 
in mind, that coincident lactose intolerance may modify the clinical outcome of some 
other (gastrointestinal) disease (114). 
 
The role of adult-type hypolactasia as a cause of recurrent abdominal pain (RAP) in 
children is controversial. Some studies have shown a substantial role for adult-type 
hypolactasia in the symptoms of children with RAP (167-171), whereas other studies 
have concluded that adult-type hypolactasia seems to be of little importance in RAP 
(172, 173). Based on these studies, it seems that in populations with high prevalences 
of lactase non-persistence, adult-type hypolactasia appears to be a major cause of 
RAP (110).  
 
3.3.6 Lactose malabsorption in secondary disaccharidase deficiency 
 
Activities of all disaccharidases diminish in the presence of mucosal injury:  the more 
severe the damage, the greater the decrease in enzyme activity (55, 99, 148, 174-177). 
Lactase, compared to the other duodenal disaccharidases, is located most distal on the 
villus, and thus is the first and usually the one most severely affected. This is referred 
to as secondary lactase deficiency (2). The activity of lactase in secondary 
hypolactasia does not decline to such low levels as in primary hypolactasia. The 
recovery, however, takes a longer period than that of villous structures (109). In active 
coeliac disease, the recovery of the lactase activity during a gluten-free diet occurs 
slowly (2, 99, 178). In malnourished infants lactase and sucrase activities are 
decreased concomitantly with the degree of villus atrophy. In these malnourished 
children lactase mRNA was reduced to 32% and sucrase to 61% of normal (177). The 
decrease in the activity of lactase is particularly marked in cases of malnutrition 
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combined with protein deficiency (109). Other causes of secondary lactase deficiency 
are for example gastroenteritis (infectious diarrhea) (55), chronic diarrhea (179), HIV 
or rotavirus infection (180, 181), giardiasis (182), extensive gastrointestinal 
operations (108) as well as antibiotics such as neomycin (183), which may cause 
villous atrophy. Alcohol has also been shown to decrease disaccharidase activities 
(184). However, as mentioned earlier, secondary disaccharidase deficiencies are 




4. GENETICS OF ADULT-TYPE HYPOLACTASIA 
 
4.1 Evolution of lactase persistence  
 
Dairying is estimated to have originated approximately 7 000 - 10 000 years ago (11, 
185, 186). That is when man began to utilize milk after weaning, and lactase 
persistence, contributing to the added nutrition from dairying, became advantageous 
(108). A culture historical hypothesis states that populations that adopted a culture 
that relied on milk as a main nutritional source co-directed their own biological 
evolution by creating a selection pressure for lactose tolerance. This hypothesis is 
supported by findings that the frequency of lactase persistence phenotype is strongly 
correlated with the dairying history of the population (107). Moreover, in cows, the 
highest gene diversity in milk protein genes is seen in Europe where there is a high 
prevalence of lactase persistence, suggesting a gene-culture co-evolution between 
cattle and humans (187). Furthermore, epidemiological studies have shown that the 
development of dairying indeed preceded selection for lactase persistence (188).  
 
The haplotype carrying lactase persistence is estimated to having undergone strong 
positive selection during the previous 10 000 years (108, 186, 189-194) (Enattah NS, 
et al, unpublished data). This short time of only about 400 generations suggests a 
selective pressure that has been estimated to be among the strongest seen for any gene 
in the genome (191). This is supported by 1) the lactase persistence haplotype is 
exceptionally long (almost identical for nearly 1 Mb), and given it has a high 
frequency of 77% in Northern Europeans 2) the SNPs near the LCT gene show large 
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differences in allele frequencies among populations (191). Relative extended 
haplotype homozygosity (REHH) showed a very high genetic differentiation across 
this region between European Americans (dairying) and Asian/African Americans 
(non-dairying). This is suggestive for genetic hitchhiking of markers on the haplotype 
of lactase persistence (191). This study reported a selection-coefficient of 1.4 – 15% 
for lactase persistence, which is consistent with the 5% previously predicted using 
gene-culture co-evolutionary model (195). 
  
4.2 Prevalence of adult-type hypolactasia 
 
The prevalence of adult-type hypolactasia has marked variation between races and 
populations. The use of different indirect diagnostic methods of varying sensitivity 
and specificity, varying diagnostic criteria as well as in some studies considerably 
small numbers of participants, makes the evaluation of the studies on the prevalence 
of adult-type hypolactasia in different populations difficult (50, 128).  The prevalence 
of adult-type hypolactasia is lowest in populations of Northern Europe. In Denmark 
and in Sweden the frequency of lactose malabsorbers is expected to be only around 1-
5% (50). However, based on the molecular diagnosis (8) the prevalence in Sweden 
seems to be somewhat higher, around 10% (196). The regional prevalence rates in 
Finns are the best characterized of all the populations. The frequency of adult-type 
hypolactasia ranges from about 8% in Swedish-speaking Finns to 14% in Western 
Finland and finally to approximately 23% in Eastern Finland (8, 129, 197-199), with a 
mean of 18% in the capital region (Tikkakoski, submitted). The prevalence of adult-
type hypolactasia is clearly higher in Southern Europe and is approximately 30% in 





























In general, adult-type hypolactasia is more common in populations outside Europe. In 
Caucasians and their descendents in North America and Australia the prevalence of 
adult-type hypolactasia is low. In American whites, the prevalence is in the order of 
15%, in African Americans about 80% and in Mexican American approximately 53% 
(50, 128). The prevalence in Latin America is generally high, around 70% in Mexico 
and 65% in Uruguay.  In Asia, the prevalence is lower in the western parts: in 
Northern India around 30% and in Southern India 60-70%. The world’s highest 
prevalences are in the populations of the Far East: in Thailand it is as high as 97-
100%, and in Indonesia 91%. In China a prevalence of adult-type hypolactasia of 
approximately 90% is observed (50, 128).  
 
The prevalence of adult-type hypolactasia in the black African populations ranges 
from 70 to 95%. Prevalence figures >90% are observed among populations with low 
milk consumption such as those in Nigeria and Zaire (50). However, interesting 
exceptions are the populations with tradition of milk consumption, nomads and the 
people who raise cattle, among whom the prevalence of hypolactasia is around 10-
20% (50). For example, in nomadic Fulani in Nigeria the prevalence of adult-type 
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hypolactasia is 22% and in cattle-raising nomads in Beja, in northeastern Sudan, 17%. 
Among Nilotes, seminomadic cattle breeding tribes in southern Sudan, the prevalence 
is up to 75% (50, 200).  
 
4.3 Adult-type hypolactasia- a genetically determined condition 
 
Lactase non-persistence was in 1973 concluded to be controlled by an autosomal 
recessive single gene (7). These results were based on analysis of segregation of 
adult-type hypolactasia in Finnish families with the diagnosis of the lactase 
persistence status with LTTE, including subjects older than the manifestation age of 
adult-type hypolactasia in the Finnish population (7). Results of a Hungarian twin 
study supported the finding: the lactase phenotype had a complete concordance in 
monozygous twins. In dizygous twins the adult-type hypolactasia prevalence was 
compatible to the prevalence in the Hungarian population (201). A trimodal 
distribution in lactase activity, representing the homozygous recessive, heterozygous 
and homozygous dominant subjects was subsequently reported in several studies 
(202-204). 
 
The observation of the trimodal distribution of lactase activity implied that the lactase 
persistence/non-persistence trait most likely was due to cis-acting differences, i.e. 
some polymorphism(s) within or near the lactase gene. This was supported by an 
expression study of the lactase mRNA transcripts from persistent and non-persistent 
individuals using polymorphisms residing in exons of the lactase gene as markers. 
The results clearly showed differential expression of the alleles of the lactase gene in 
subjects with intermediate lactase activities (71). Despite the cloning and the 
sequencing of the complete cDNA and 1 kb of the promoter region of the lactase 
gene, no sequence differences segregating with the lactase persistence trait had been 
identified until recently (27, 28, 74, 205, 206). Using the single nucleotide 
polymorphisms (SNPs) in the region four 60-kb haplotypes were identified, and three 
of them exist in Europe. One haplotype (haplotype A) associated significantly with 
high lactase expression (189). This haplotype was the most frequent in northern 





4.4 Identification of a DNA variant associated with adult-type hypolactasia 
 
In an effort to identify the cis-acting variant associating with adult-type hypolactasia, 
Enattah et al. (8), to begin with, analysed the region flanking the LCT gene at 2q21 by 
genotyping seven polymorphic microsatellites in nine well-characterized Finnish 
families with known lactase persistence/non-persistence status (202). Traditional 
linkage analysis and using recombination events that define the centromeric and 
telomeric boundaries for the locus narrowed the region to approximately 5 cM. Nine 
polymorphic markers within this region that showed best evidence for linkage were 
chosen for fine mapping.  Six markers spanning a 200 kb region showed highly 
significant evidence for linkage disequilibrium (LD): the strongest LD was detected 
on the LCT gene and 5’ of the LCT gene, but no evidence for LD on markers 3’ of the 
LCT gene.  Based on analyses of constructed haplotypes within the families, using 
seven of the markers, the locus for lactase persistence was restricted to a 47-kb 
interval, covering only one gene, MCM6 (minichromosome maintenance 6). The 
restriction of the locus was made based on two chromosomes differing from the 
ancestral ones only at one marker. This restriction has been criticized (97, 190, 191) 
and claimed to have been caused by recent mutation at the marker instead of a 
recombination event. However, later on an identical prevalence of the specific allele 
at the marker in question among unrelated individuals (n=262) with lactase 
persistence as well as lactase non-persistence has been demonstrated (208).  
 
Sequence analysis of the 47 kb region upstream of the LCT gene resulted in the 
identification of a total of 52 non-coding variants. Two of the variants, C to T-13910 
(dbSNP rs4988235), and G to A-22018 (dbSNP rs182549), showed complete co-
segregation with lactase persistence. The C/T variant is located 13,910 base pairs 
from the initiation codon of the LCT gene, in intron 13 of the MCM6 gene, and the 
G/A variant 22,018 base pairs upstream of LCT, in intron 9 of MCM6 (Figure 6). 
Further analysis of the variants in Finnish as well as in non-Finnish subjects with 
biochemically determined lactase activity, gave further support for the complete 
association of the C/T-13910 polymorphism with the lactase persistence/non-persistence 
trait.  The G/A-22018 did not segregate with lactase activity in all cases suggesting that 
it was only in LD with the causing variant. Furthermore, the prevalence of the C/C-
13910 genotype in samples from Finnish, French, North American and African 
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Americans subjects studied was consistent with the epidemiological data on the 
prevalence of the adult-type hypolactasia in the population in question. Accordingly, 
the C/C-13910 genotype, based on these findings, was concluded to associate with 
adult-type hypolactasia, whereas subjects with the genotypes C/T-13910 and T/T-13910 
were shown to be associated with lactase persistence (8).  
 
Figure 6. Location of the SNPs suggested being associated with adult-type 














4.5 Functional studies 
 
Since the identification of the C/T-13910 variant associated with adult-type hypolactasia 
several studies have explored its functional significance. Quantitation of relative 
expression of the LPH mRNA transcripts from the C-13910 and T-13910 alleles by allele-
specific reverse transcription polymerase reaction (RT-PCR) in Finnish adults, 
showed several times higher expression of LPH mRNA from the T-13910 allele (209). 
Two groups have separately studied the gene regulatory activity of the -13910 region 
by transfecting the intestinal Caco-2 cell line with constructs of the -13910 region, 
lactase promoter and luciferase reporter gene. Both studies showed that the –13910 
region contains a strong enhancer, the T-13910 variant enhancing the LPH promoter 
more strongly (96, 210). Furthermore, in electrophoretic mobility shift assay (EMSA) 
nuclear protein interaction showed a stronger nuclear factor binding to the T-13910 
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compared to the C-13910 allele (96, 210). Recently, transcription factor Oct-1 and 
glyceraldehyde-3-phosphate (GADPH) were co-purified by DNA affinity purification 
using the sequence of the T-13910 variant (211). In supershift analysis, Oct-1 bound 
directly to the T-13910 allele. Co-expression with HNF1α stimulated lactase gene 
expression. GADPH was suggested to interact with Oct-1. In addition, binding sites to 
intestinal transcription factors GATA-6, HNF4 α, Fox and Cdx-2 were also identified 
in the –13910 region, providing further support that this region underlies the 
developmental regulation of lactase expression in human (211).  
 
 The function of the MCM6 (minichromosome maintenance 6) gene where the C/T-
13910 variant is located is relatively poorly known.  MCM6 is the human homologue of 
a yeast cell division cycle gene, showing similarity to rat intestinal crypt-cell licensing 
factor. MCM6 transcripts are expressed in all tissues studied, both in fetuses, children 
and adults. Accordingly, MCM6 is not restricted in its tissue distribution and does not 
show age-related variation in the level of expression in the human intestine, in 
contrast to the expression of lactase gene (212). 
 
4.6 Correlation of the C/T-13910 genotypes with the phenotype  
 
During the time the work was being done for this thesis, a few studies have assessed 
the correlation of the C/T-13910 genotypes with the lactase persistence phenotype in 
populations outside Finland. A common weakness in these studies has, however, been 
the lack of the biochemically determined lactase activity as a definition of the lactase 
persistence/non-persistence status of the subjects studied. As previously discussed, the 
results of the indirect tests are not reliable in all cases.  
 
In a study with Austrian subjects, the 24% frequency of the C/C-13910 was concordant 
with the frequency of lactose intolerance diagnosed by the breath hydrogen test 
(BHT) in individuals from the same region (137). In another Austrian study, a 97% 
correlation was observed between the C/C-13910 genotype and a positive test result in 
BHT. Of those with C/T-13910 and T/T-13910 genotypes 14%, however, had a positive 
BHT (213). In a German cohort, the frequency of the C/C-13910 genotype was 21.4%; 
somewhat higher than that diagnosed by BHT (15%) (214). In a Swedish study, the 
results from LTT correlated perfectly with the genotyping results in subjects C/C-13910 
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and T/T-13910 genotypes, whereas in three subjects with C/T-13910 genotype the result in 
LTT was suggestive of lactose malabsorption (215). Another Swedish study gave 
similar result: in 94% of the cases the results on genotyping and LTT were concordant 
(216). The results from a British laboratory showed perfect association between the 
C/T-13910 genotypes with lactase persistence/non-persistence phenotypes in Northern 
European samples studied but not in 2/40 Southern European samples (190, 217). 
Complete correlation of transcript expression level and the C/T-13910 genotype, could 
neither be demonstrated (190, 217).  
 
A recent study reports the C/T-13910 variant frequencies in 20 distinct African cultural 
groups (218). For seven of the 20 groups phenotype data was available in the 
literature. In the sub-Saharan groups the T-13910 allele was found too seldom in order 
to underlie the lactase persistence phenotype, thus it was suggested that C/T-13910 
might not be the causing variant in these groups.  (218). Despite the fact that the 
definition of the phenotype was not reliable in this study it seems possible that another 
variant may underlie the lactase persistence in those populations; however, more 
studies on the issue are warranted. Taken together, these data suggest an excellent 
correlation between C/T-13910 polymorphism and lactase persistence/non-persistence 
phenotype in all populations- except for the sub-Saharan Africans- studied so far.  
 
 
5. DISEASES ASSOCIATED WITH DAIRY PRODUCT CONSUMPTION 
 
5.1 Cow’s milk allergy (CMA) 
 
Cow’s milk allergy (CMA) is an immunologically mediated adverse reaction to cow’s 
milk proteins, which usually develops soon after introduction of cow’s milk into the 
diet.   CMA affects approximately 2-3% of infants during the first two years of life 
(219, 220). In most cases CMA is transient: approximately half of the cases have 
developed tolerance to cow’s milk by three to four years of age (221). In a Finnish 
follow-up study 15% of the subjects at a mean age of 8.6 years had not recovered 
from CMA (222). Adult-onset CMA is rare (<1%) and usually much milder than in 
infants (223). The treatment of CMA consists basically of as strict as possible 
avoidance of cow’s milk (223).  
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The casein fraction (αS1-, αS2-, β-, and κ-casein) accounts for 80% of cow’s milk 
proteins. The whey fraction (20%) contains globular proteins of which the major ones 
are α-lactalbumin and β-lactoglobulin. Bovine serum albumin (BSA) and lactoferrin 
are detected in smaller amounts. In up to 75% of the subjects with CMA, 
polysensitization occurs to several proteins, thus no single protein or protein structure 
can be taken to account for the major part of milk’s allergenicity (224). Possible 
contamination of lactose with trace amounts of milk proteins is the reason why infant 
formulas used in the treatment of CMA do not contain lactose. However, children 
with CMA are clinically tolerant to lactose and need not to exclude foods or 
pharmaceutical preparations containing lactose (225).  
 
5.1.1 Clinical features of CMA 
 
The symptoms of CMA involve several organs: skin (urticaria), respiratory tract 
(rhinitis) and gastrointestinal tract (most commonly vomiting, pain, diarrhea), but in 
the worst cases CMA may result in anaphylactic shock (226). The time when the 
symptoms appear varies from minutes to hours; delayed-type reactions take days, or 
even up to two weeks.  The reactions of the skin are usually immediate, whereas in 
the delayed-type reactions gastrointestinal symptoms predominate (227). The 
immediate-type reactions are usually IgE-mediated, whereas the mechanisms which 
associate with the delayed-type reactions are poorly understood, and only some of the 
reactions are IgE-mediated (219). Based on a recent follow-up study, all children 
diagnosed with a non-IgE CMA had become tolerant to cow’s milk by the age of five 
years, but in those with IgE-mediated CMA, the hypersensitivity often persisted up to 
school age (222). Cow’s milk protein-sensitive enteropathy (CMSE), on the other 
hand, is a condition, which manifests mainly in the gastrointestinal tract with the 
typical findings in endoscopy being visible lymphonodular hyperplasia of the 
duodenal bulb and lymphoid follicles without villous atrophy (228). CMSE may 
persist or manifest for the first time in older children. The prevalence and significance 






















GI, skin, respiratory GI Symptoms 
Immunologic Enzyme deficiency Mechanism 
Bovine milk proteins Mammalian milk sugar Offender 
Infancy Childhood/Adulthood Age 
Low High Racial variation 
Low High Prevalence 
Cow’s milk allergy Adult-type hypolactasia 
 
5.2 Colorectal carcinoma (CRC) 
 
Colorectal carcinoma (CRC) is one of the most frequent types of cancer in Western 
industrialized countries. In comparison with other countries, Finland has low colon 
cancer rates in both genders (229).  CRC is causally related to both genetic 
susceptibility and environmental factors. To mention a few, p53, DNA mismatch 
repair (MMR) genes, H-ras, and the genes of the APC- β-catenin- Tcf –pathway are 
often mutated in CRC (230). In the classic pathway of the adenoma-carcinoma 
sequence accumulation of several mutations –including those activating oncogenes as 
well as those inactivating tumor-suppressor genes– is considered a requisite for 
carcinoma development (231, 232). It is commonly agreed that the risk of colorectal 
cancer is modified by food and nutrition. Among the environmental factors meat and 
alcohol consumption and smoking are regarded as significant risk factors, whereas 
inverse association has been observed with the consumption of vegetables, physical 
activity and non-steroidal anti-inflammatory drugs (NSAIDs), among others (230). 
There are numerous theories on the interactions of the specific molecular and 
environmental factors behind CRC development (230). 
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 5.2.1 Dairy products in CRC 
 
Various epidemiological studies have tackled the role of dairy products in the 
development of CRC, and several cohort studies suggest a modestly reduced risk of 
CRC with the consumption of dairy products (229, 233, 234). It is of interest that two 
of them suggesting a protective effect (229, 233) were carried out on the Finnish 
population, in which the milk consumption is among the highest in the world (235). In 
theory, several components of dairy products could increase or decrease the risk of 
CRC. The following different components of the milk have been suggested to mediate 
the protective effect: calcium (229, 234, 236-240), vitamin D (234, 236-240), lactose 
(233), lactoferrin (241) and conjugated linoleic acid (242). Milk fats, particularly the 
saturated fats, may increase the CRC risk (234). The role of the individual 
components on the carcinogenic process, however, is extremely difficult to dissect.   
 
5.2.2 Role of colonic microbiota  
 
Colonic microbiota, whose main function is to degrade and ferment potential energy 
sources reaching the colon, is a major environmental factor that modulates the risk of 
colorectal cancer (243). Some of short-chain fatty acids produced in degradation have 
been proposed to be related to colorectal carcinogenesis (244). Probiotics are cultures 
of live microorganisms which, when applied to animal or man, beneficially affect the 
host by improving the properties of the indigenous microbiota. In animal models 
treatment with probiotics has been shown to reduce the prevalence of CRC (245). 
Prebiotics, in contrast, are non-digestible food components, that reach the colon in an 
intact form, and stimulate the growth or activity of bacteria such as Lactobacilli and 
Bifidobacteria (246). Some of these strains bind the surface of colonic epithelial cells 
in culture, and thus may hypothetically protect the surface by facilitating repair and 
reducing irritation at the colonic epithelium (234). In low risk populations of CRC 
high concentrations of some of Lactobacilli species and Eubacterium aerofaciens 
have been observed in comparison to high risk populations (247, 248). In subjects 
with lactose malabsorption, lactose has been suggested as a natural prebiotic, and 
therefore might be of relevance in the pathogenesis of CRC (246). Lactose 
malabsorbers consuming dairy products have thus been suggested to have less of a 
risk for CRC (249).  
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AIMS OF THE STUDY 
 
The aims of this study were: 
 
1) To study the timing and mechanism of developmental downregulation of 
lactase activity during childhood  
2) To assess the applicability of the genetic test of the C/T-13910 variant as a 
screening method for adult-type hypolactasia  
3) To clarify the prevalence of various gastrointestinal symptoms and 
consumption of milk products in Finnish children and adults with molecularly 
defined adult-type hypolactasia 
4) To study the relationship between adult-type hypolactasia and the 























MATERIALS AND METHODS 
 
 
1. STUDY SUBJECTS 
 
1.1 Age of lactase downregulation 
 
This study included 329 children undergoing gastrointestinal endoscopy for 
abdominal complaints. Of them 252 were Finnish (mean age 9 years; range 0.6-20.2), 
65 of Somalian origin (mean age 6.9 years; range 0.1-15.6 years) and 12 of other 
Caucasian origin (mean age 6.9 years; range 1.9-10.9 years). They all lived in 
Finland. Duodenal biopsies, 10-20 cm distal to the ligament of Treitz, were obtained 
in endoscopies at the Hospital for Children and Adolescents, University of Helsinki 
between 2001 and 2003. The biopsy sample was divided into two parts: one was used 
for routine histological examination and the second for assaying the disaccharidase 
activities and subsequent DNA extraction. Of the Finnish families 28% (n=71) 
completed a questionnaire about the child’s milk consumption and possible milk 
related symptoms.  
 
1.2 Mechanism of lactase downregulation 
 
For this study, duodenal biopsy specimens from 45 Finnish children aged between 10 
months to 23 years were obtained at the Hospital for Children and Adolescents, 
University of Helsinki in 2003-2004. The biopsy specimen was divided into three 
pieces: one for routine histological examination, the second for assaying 
disaccharidase activities and subsequent DNA extraction, and the third part for total 
RNA extraction. The specimens were analysed for the coding SNP G/A+593 on exon 1 
of lactase (LPH) gene and those heterozygous for the G/A+593 (n=15) (age range: 10 
months to 23 years, mean age: 7.4 years) were chosen for the actual study (Figure 7). 
The clinical diagnoses of these children were suspected gastroesophageal reflux 
(n=12), abdominal pain of unknown origin (n=1), H.pylori infection (n=1) and 






Figure 7. Flowchart of sample processing  
 












Genotype C/T-13910 n (%) Of which A/G+593 heterozygotes (n) 
C/C 5 (13.5%) 3 
C/T 19 (51.4%) 12 
T/T 13 (35.1%) 0 




RNA extraction (A/G+593 heterozygotes)  
 
 
1.3 Adult-type hypolactasia and cow’s milk allergy 
 
This study included 172 children (mean age 8.6 years) of whom 93 (54%) had a 
previous diagnosis of cow’s milk allergy (CMA) and 79 (46%) were controls. They 
all had participated in a study, in which 6209 unselected infants born between 1994 
and 1995 in the Helsinki region were followed from birth for the development of 
CMA (220). At the age of 8-9 years, during August 2003 to March 2004, these 
children were clinically examined at the Helsinki University Central Hospital and 
taken a blood sample for analysis of the C/T-13910 variant of adult-type hypolactasia. 
At that time families were also asked about the child’s milk consumption and possible 






1.4 Adult-type hypolactasia among Finnish adults  
 
This study included 1900 working age adults (age range 18-64 years, mean age 46.5 
years) from the capital area of Finland attending primary health care. They gave a 
blood sample from which DNA was extracted and used for genotyping the C/T-13910 
variant of adult-type hypolactasia. The participants also filled in questionnaires 
developed for this study. The questions concerned various gastrointestinal symptoms, 
the daily consumption of dairy products and possible milk related symptoms. The 
response rate was extremely high, 99.3%. The collection of the questionnaires and 
blood samples occurred during a three-month period through February to May 2004. 
 
1.5 Adult-type hypolactasia and colorectal carcinoma 
 
In this study DNA samples from a total of 2766 subjects were analysed for the C/T-
13910 variant of adult-type hypolactasia. The samples comprised 963 Finnish, 283 
British and 163 Spanish subjects with colorectal cancer, and 773 Finnish, 363 British, 
and 221 Spanish control subjects. The Finnish controls were frequency matched to the 
cases, and derived from the same geographical provinces as the cases. The Spanish 
cases and controls were all derived from Catalonia, and the UK subjects were all 
primarily derived from Southern England. Clinical data, including age at the time of 
diagnosis, sex, tumour histology, stage and site of the tumour were obtained from 





















 I II III IV V 
Assay of disaccharidases x x    
DNA extraction x x x x  
RNA extraction  x    
PCR/Minisequencing x x x x x 
Sequencing  x x    
RT-PCR and quantitation mRNA levels  x    
Analysis of dairy consumption and GI-symptoms based on 
a questionnaire 
x  x x  
Statistical methods x x x x x 
 
 
2.1 Assay of intestinal disaccharidases 
 
 
Lactase, maltase and sucrase activities were determined at the laboratory of the 
Hospital for Children and Adolescents, University of Helsinki, according to the 
method of Dahlqvist with modifications (6, 250). The assay of intestinal 
disaccharidases is based on the composition of disaccharides partly of glucose 
molecules, which are liberated on hydrolysis. The activities of the intestinal 
disaccharidases are assayed by incubating the intestinal samples with the respective 
disaccharides, after which the amount of glucose liberated is measured using Tris-
glucose oxidase reagent and a direct correlation to the activity of the intestinal 
disaccharidase studied is obtained.  Tris-buffer is used to inhibit contaminant 
disaccharidases (6, 250).  
 
Accordingly, the duodenal biopsies were weighed, solubilized in cold NaCl (100 
µl/mg tissue) and homogenized on ice for 45 seconds. After centrifugation (4500 
rpm/15 min) supernatants were diluted in cold NaCl, pipetted on a Deep Well plate 
(ABgene, Epsom, UK), mixed by vortexing and incubated in 37˚C for 60 minutes. 
After that 300 µl of icecold glucose oxidase reagent (Sigma-Aldrich, Helsinki, 
Finland) was added to each well and incubated again in 37˚C for 60 minutes. Finally, 
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the absorbance of the samples was measured at 450 nm on a Multiscan 
spectrophotometer (Bio-Rad Laboratories, Espoo, Finland) and the activity of the 
disaccharidases calculated as units of enzyme activity. One unit (U) is defined as the 
activity of a disaccharidase required for hydrolyzing 1 µmol of disaccharide per 
minute. Lactase deficiency was diagnosed when the activity of lactase was < 10 U/g 
protein and lactase/sucrase ratio < 0.2 (4, 6, 163). The activities of maltase and 
sucrase were determined in order to exclude patients with secondary lactase 
deficiency. 
 
2.2 DNA extraction  
 
 
DNA extraction was carried out using standard protocols: by phenol-chloroform 
extraction for DNA extraction from duodenal specimens, and using Puregene kit 
(Gentra Systems, Minneapolis, USA) for DNA extraction from whole blood samples.  
 
 
2.2.1 DNA extraction from duodenal biopsies 
 
 
After the assessment of disaccharidase activities, the intestinal specimens were used 
to extract the DNA. The sample was moved into a proteinase-K buffer (0.5% SDS, 
0.1M NaCl, 50mM Tris pH 8.1, 20mM EDTA) and proteinase K (20mg/ml) was 
added in order to dissolve the proteins. After an overnight incubation at 37˚C the 
DNA was extracted by phenol-chloroform extraction (251). Precipitation of DNA was 
done at –70 ˚C for 15 min after addition of 2.5 vol cold ethanol and 1/10 vol 3M 
NaAc.  Finally the samples were centrifuged, washed with 70% ethanol, lyophilized 
and solubilized in dH2O. 
  
2.3 RNA extraction from duodenal biopsies 
 
 
Total RNA was extracted using the standard protocol for the RNeasy mini kit 






2.4 Polymerase chain reaction (PCR) and reverse transcriptase PCR (RT-PCR) 
 
DNA fragments were amplified by polymerase chain reaction –amplification. The 
following PCR protocol was used for amplification of the C/T-13910 variant followed 
by minisequencing: the PCR amplification was carried out in a 50 µl volume with 30-
100 ng DNA, primers (one biotin-labeled (5 µM) and one unmodified (50 µM)), 
dNTPs (1000 µM), 0.5 U of Taq polymerase (Dynazyme, Finnzymes) in a standard 
buffer. The PCR cycle conditions used were as following: an initial round of 
denaturation at 94 ˚C for 4 min, then 35 cycles at 94 ˚C for 30 s, 53 ˚C for 30 s, 72 ˚C 
for 1.15 min, and a final extension of 72 ˚C for 10 min. The resulting PCR products 
were analyzed by 1.5% agarose gel electrophoresis to verify the amplification and the 
size of the PCR product. See table 5 for the primer sequences. 
 
Table 5. Sequences of primers used for genotyping the C/T-13910 variant of adult-type 
hypolactasia.  
 
Primer Sequence (5’-3’) 
SNP C/T-13910 Forward primer 5’-(Biotin)CCTCGTTAATACCCACTGACCTA-3’ 
SNP C/T-13910 Reverse primer 5’-GTCACTTTGATATGATGAGAGCA-3’ 
SNP C/T-13910 Detection primer 5’-GGCAATACAGATAAGATAATGTAG-3’ 
 
 
In Study II, complementary DNA (cDNA) for lactase gene was reverse transcribed 
from total RNAs extracted from intestinal samples using 5´-
TGTCGAATCTGCTCTAAGGAG primer. The 20 µl reaction mixture contained 10 
mmol/l MgCl2, 50 mmol/l Tris-Hcl (pH 8.3), 100 mmol/l KCl, 4 mmol DTT, 1 mmol 
dNTPs, 31 U RNase inhibitor (RNAguard, Amersham Pharmacia Biotech, Little 
Chalfont, Buckinghamshire, UK), 20 pmol of the primer and 200 U of AMV (avian 
myeloblastosis virus) reverse transcriptase (Finnzymes, Espoo, Finland). RT reactions 
were performed at 50 ºC for 50 minutes. The PCR-amplifications of the cDNAs were 
performed using a biotinylated forward primer (5’-
(biotin)ACCTAGTTGGGATCTGGTTCA) and an unmodified reverse primer (5’- 
AGATATGGGTGGTTCTAGCAG), and for a G/A+593 heterozygous (in exon 1 of 
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lactase gene) genomic DNA sample using a biotinylated forward primer (5’-
(biotin)ACCTAGTTGGGATCTGGTTCA) and an unmodified reverse primer (5’-
TGTCGAATCTGCTCTAAGGAG) with a PCR-protocol of 35 cycles at 55 ºC with a 
30 second extension step at 72 ºC. The G/A+593 SNP in exon 1 of the lactase (LCT) 
gene was chosen because it previously had been shown to be the most polymorphic 
SNP of the LCT gene in the Finnish population (209). 
 
2.5 Solid-phase minisequencing 
 
In solid-phase minisequencing, firstly, PCR amplification with one biotin-labeled and 
one unmodified primer is performed. Two aliquots of the amplified sample are then 
attached to solid support coated with streptavidin.  Denaturation is carried out with 
alkaline treatment, followed by a washing step where the excess dNTPs from PCR 
and the unbiotinylated strand are removed. After that a detection primer is hybridized 
to the single-stranded template adjacent to the variant nucleotide. DNA polymerase 
will extend the primer with the [3H]-labeled dNTP if it is complementary to the 
nucleotide present at the variable site. In other words, in samples from homozygous 
individuals a labeled dNTP is incorporated in only one of the reactions and in samples 
from heterozygous individuals in both reactions. After the washing steps the sample is 
again denaturated with alkaline treatment, and the eluted radioactivity expressing the 
amount of incorporated label is measured using a scintillation counter. The results of 
the assay are numeric counts per minute (cpm), which express the amount of 
[3H]dNTP incorporated in the minisequencing reactions. The ratio (R) between the 
cpm values directly reflects the ratio between the two sequences in the original 
sample (252, 253).  
 
Briefly, in the minisequencing of the C/T-13910 single nucleotide polymorphism, two 
10-µl aliquots of the biotin-labeled PCR product were captured to straptavidin coated 
microtitre wells (Thermo Electron, Helsinki, Finland). The reaction mixture contained 
10 pmol of the detection primer (for sequence, see Table 5), 0.1 µl of either 3H-dCTP 
or 3H-dTTP (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) and 
0.05 U of DNA polymerase (Dynazyme II, Finnzymes, Espoo, Finland). The reactions 
were allowed to occur for 15 min at 56˚C before washing off the unattached label. 
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Finally, the attached detection primer was eluted by NaOH treatment and the 
radioactivity measured in a liquid scintillation counter (Rackbeta 1209; Wallac, 
Turku, Finland).   
 
2.6 Quantitation of mRNA-levels by solid-phase minisequencing 
 
For preparation of the standard curve in Study II, two total RNA samples homozygous 
either for the G+593 or for A+593 allele were mixed at varying ratios (0%, 6%, 10%, 
16%, 20%, 30%, 40%, 48%, 56%, 64%, 72%, 80%, 82% and 100% of AA+593). Using 
protocols described above, the RNA mixtures were reverse transcribed to cDNA and 
amplified by PCR. The relative amounts of G and A alleles in these mixtures, in a 
genomic DNA sample in which the alleles are present in exact 1:1 ratio and in the 
actual study samples (n=15) (two reactions per sample) were assessed simultaneously 
by quantitative minisequencing. Each PCR-amplified cDNA product was divided into 
two 10 µl reactions and captured on streptavidin-coated wells with 40 µl of 20 mmol/l 
Na2SO4 (pH 7.5), 0.15 mol/l NaCl, and 0.1% Tween 20. The microtiter plates were 
incubated for 1.5 h at 37 °C after which the wells were washed, and then incubated at 
room temperature with 50 mM NaOH to denaturate the DNA. After removing the 
unbound strand by washing the reactions were carried out for 15 min at 51 ºC with 20 
pmol of the detection primer (5’- TTTTCTGTGGGCATCACTGAG), 0.5 U of Taq 
polymerase in 1x PCR buffer and 2 pmol of tritium labeled dNTP (3H-dGTP and 3H-
dATP). The wells were washed and treated with 50 mmol NaOH for 5 min. The 
incorporated tritium-labeled nucleotides were measured in a liquid scintillation 

































Based on information of the relative amounts of G and A in the G/A+593 heterozygous 
genomic DNA sample, the concentrations of G and A in the RNA mixtures for the 
standard curve were calibrated, and an 11-point standard curve obtained. The standard 
curve was observed to be linear up to 82% (y = 0.0135x – 0.9714) and behaved 
exponentially for 82-100% (y = 1x10-5e0.1129x). The standard curve allowed us to 
relate the results of the minisequencing with the actual relative amounts of LCT 









Figure 9. Standard curve. The amount of A+593 allele in total RNA plotted as a 
function of the GA+593 ratio on a log scale.  
 















The DNA samples were amplified by PCR with the procedure as detailed above, 
sequenced using BigDye terminator chemistry, and run on an ABI377 automatic DNA 
sequencer according to the manufacturer’s instructions (Applied Biosystems, Perkin 
Elmer, Foster City, California, USA).  The analysis of the obtained DNA sequences 




2.8 Assessment of gastrointestinal (GI) symptoms and dairy consumption by 
questionnaires 
 
The participants in Studies I and III (either the children themselves or their parents) 
filled in questionnaires concerning their daily consumption of milk as a drink (normal 
and low-lactose milk), consumption of other dairy products, and possible milk related 
GI symptoms. In Study IV, we used a more comprehensive questionnaire in which the 
frequency of various GI symptoms and their relation to meals, as well as the 
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correlation of the symptoms to different type of milk products and other food was 
assessed. Questions on previous diagnosis of lactose intolerance or other GI disease 
such as colon cancer, celiac disease, or Helicobacter pylori infection were also 




2.9 Statistical methods 
 
All statistical analyses were performed using SPSS for Windows, release 11.5.1 
(SPSS Inc., Chicago, Illinois, USA). Frequency differences were analysed with 









































1. TIMING AND MECHANISM OF DOWNREGULATION OF LACTASE 
ACTIVITY DURING DEVELOPMENT 
 
We applied the recently identified C/T-13910 variant associating with adult-type 
hypolactasia as a molecular marker to study the timing and mechanism of 
developmental downregulation of lactase activity during childhood. The aim was, in 
the first place, to obtain information on whether the C/T-13910 genotypes correlated 
with the biochemically determined lactase activities of children at various ages and 
ethnicities. Accordingly, if the C-13910 allele indeed has a causative role in the 
development of adult-type hypolactasia, we should be able to detect the age at which 
lactase activity is downregulated in those children with the homozygous C/C-13910 
genotype. Furthermore, by studying several ethnic groups we would be able to 
examine the reported variation in the age of lactase downregulation between 
populations (Study I). In the next step, we extended the approach and investigated the 
mechanism of the developmental downregulation of lactase activity.  For this, we 
obtained intestinal biopsies from children at various ages, and quantitated the relative 
lactase mRNA expressed from the C-13910 and T-13910 alleles, respectively (Study II). 
 
1.1 Timing of lactase downregulation  
 
The prevalence of the C/C-13910 genotype of adult-type hypolactasia among the 329 
children participating in Study I and representing three ethnic groups was as follows: 
14.7% in the Finnish, 75.0% in the other Caucasians, and 95.4% in the African 
children. The prevalence figures are in the range we expected (50), and it is to be 
noted that all of the children from Somalia had the C/C-13910 genotype. We 
additionally genotyped the G/A-22018 variant (8) that shows a 98% association with the 
lactase persistence/non-persistence trait. In all cases except for two of the Finnish 
subjects, the G/G-22018 genotype was present in children with the C/C-13910 genotype. 
The younger of the two subjects with genotype combination C/C-13910 and G/A-22018, 
aged five, still had high lactase activity, but the other child, aged ten years, had low 
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lactase activity (5 U/g protein), giving further evidence for the conclusion that the 
G/A-22018 variant is only in linkage equilibrium with the causing variant (8). 
 
In the combined study population representing various ethnic backgrounds and ages, 
the mean lactase activity in children with the C/C-13910 genotype was 13.8 U/ protein, 
in those with C/T-13910 genotype 33.1 U/g protein and in those with T/T-13910 genotype 
50.4 U/g protein, demonstrating a trimodal distribution of lactase activities, as 
expected (7, 202-204).  Among those with the C/C-13910 genotype aged > eight years, 
93% had low lactase activity, here defined as lactase activity < 10 U/g protein or 
lactase to sucrase (L/S) ratio < 0.2. In all children with the C/C-13910 genotype who 
were > 12 years of age, lactase activity had decreased to < 10 U/g protein (Study I) 
(Figures 10 and 11). An analysis of disaccharidase activities in 39 random samples 
from adolescents aged 12-18 years genotyped for the C/T-13910 polymorphism who 
had undergone endoscopy at the Hospital for Children and Adolescents, University of 
Helsinki during a two-year period between 2003 to 2005 also showed that the subjects 
with the C/C-13910 genotype (n=5) presented with low lactase activity of < 10U/g 
protein whereas all those with genotypes C/T-13910 and T/T-13910 (n=34) had lactase 
activity ≥ 10 U/g protein (Rasinperä, unpublished data). The decline of lactase 
activity in Study I occurred somewhat earlier among the African children with the 
C/C-13910 genotype (Figure 11). Among those < five years of age, 67% of Africans 
compared to 25% of the Finnish children had lactase activity < 20 U/g protein 
(p<0.04). However, the disaccharidase activities in African children were overall 
lower than in Finnish children, as reported earlier (56), and the difference in the age 
of lactase downregulation was not significantly different when lactase activity < 20 
U/g protein was used as the cut-off value. In the other Caucasian children with the 
C/C-13910 genotype, lactase activity had decreased to < 10 U/g protein in all children 







































Among the children with C/T-13910 and T/T-13910 genotypes defining lactase 
persistence, lactase activity was > 10 U/g protein in 98% of the cases. Of the four 
cases with lactase < 10 U/g, three had the C/T-13910 genotype and one the T/T-13910 
genotype. One of these children was diagnosed to have congenital lactase deficiency 
(CLD) and another was carrier of a CLD mutation on the T-13910 allele-carrying 
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chromosome, and was confirmed to be a lactose malabsorber by LTT.  The two other 
children had borderline lactase activities of 9 U/g protein with L/S ratios of 0.21 and 
0.22, respectively; both had gastrointestinal symptoms when on a low lactose 
containing diet.  
 
1.2 Mechanism of lactase downregulation 
 
 
To further assess the role of the C-13910 allele in the downregulation of lactase activity 
(Study II), we collected an additional set of samples from children undergoing upper 
gastrointestinal endoscopy.  An additional biopsy was taken from them, in order to 
measure the lactase expression at the mRNA level. We used G/A+593 polymorphism in 
exon 1 of the LCT gene as a marker of relative lactase mRNA expression. 
Consequently, we isolated total RNA from intestinal biopsy samples with verified 
disaccharidase activities in children heterozygous for this polymorphism (n=15). 
Twelve of them were heterozygous for the lactase persistent C/T-13910 genotype and 
three homozygous for the lactase non-persistent C/C-13910 genotype. The subjects with 
the C/T-13910 genotype had high lactase activity (mean activity of 47 U/g protein) 
except for one child who had a lactase activity of 6 U/g protein. This child was later 
shown to be a carrier of a CLD mutation. Of the three subjects with the C/C-13910 
genotype, one, who was 23 years, had low lactase activity (6 U/g protein), a five-year 
old subject had high lactase activity (24 U/g protein) and from one subject lactase 
activity was not available. 
 
In order to quantitate the relative expression levels of the C-13910 and T-13910 allele we 
used the allele-specific reverse transcription-polymerase chain reaction (RT-PCR) 
followed by solid-phase minisequencing. Our results showed that lactase mRNA was 
transcribed from both the C-13910 and T-13910 allele in children younger than five years 
in a 1:1 ratio.  In those children over six years of age, the relative lactase mRNA 
expression from the C-13910 allele was reduced to 18% and 16% compared to that from 






Figure 12. Relation of age to the relative expression of LPH mRNA from the C-13910 


























These two studies are the first to explore the timing of downregulation of lactase 
activity in children genetically tested for the C/T-13910 variant associated with lactase 
persistence/non-persistence. Our findings demonstrate, both at the protein and at the 
mRNA level, a causative role for the C-13910 allele in the development of adult-type 
hypolactasia in subjects with the C/C-13910 genotype.  To conclude, 1) we have 
observed a marked imbalance in relative lactase mRNA expression levels from the C-
13910 compared to the T-13910 allele in children aged > five years. Moreover, the 
expression of the transcribed lactase mRNA from the C-13910 allele (Study II) declines 
around the same age when the developmental downregulation of lactase activity 
occurred (Study I). 2) The prevalence of the C/C-13910 genotype in the ethnic groups 
(Study I) was well in agreement with the reported prevalence of lactose malabsorption 
in the Finnish and African populations (50), and 3) the trimodal distribution of lactase 
enzyme activity according to the C/T-13910 genotype groups (Studies I and II), further 
demonstrates an association of the C/T-13910 variant with the lactase persistence/non-
persistence trait.  
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The age of onset of adult-type hypolactasia has been reported to vary between 
populations (50). In the Finnish population adult-type hypolactasia has been reported 
to manifest up to 20 years of age (62, 63). Our study, however, suggests that lactase 
activity is indeed downregulated in Finnish children with the C/C-13910 genotype by 
the age of 12 years. Studies on the age of onset of adult-type hypolactasia in subjects 
of African origin are scarce in number. Welsh, et al, have reported that adult-type 
hypolactasia develops after the age of three years in black children; the exact ethnic 
background of the subjects, however, was not reported (55). In another study the 
prevalence of lactose intolerance based on LTT in black children living in Boston, 
USA, was reported to have an increasing gradient from 11% at the age of 4-5 years to 
72% in subjects aged 8-9 years (254). We noticed (Study I) that the difference in the 
age at which lactase activity is downregulated between the two genetically diverse 
populations, Finnish and Somali, is somewhat smaller than previously reported in the 
literature (50, 55, 254). Lactase mRNA expression was only examined in Finnish 
children (Study II). We did not observe any difference in the relative expression levels 
from the C-13910 and T-13910 alleles in children younger than four to five years of age. 
Variations in the levels of lactase enzyme activity and L/S ratio may indicate 
differences in other regulatory factors (36, 89, 91, 92, 94, 211, 255) or 
posttranscriptional modifications (73). Naturally, the level of lactase expressed as U/g 
protein, is also to a great extent influenced by technical variations and the site where 
the biopsy specimen is obtained; in our studies this bias, however, can be considered 
minimal since all endoscopies were carried out at the same hospital and by 
experienced surgeons. The regulatory mechanisms underlying the reported ethnic 
differences in the timing of downregulation of lactase activity, however, are so far 
poorly understood. 
 
Our results (Study II) about the transcriptional regulation of the lactase gene support 
the earlier findings by researchers in other laboratories (69-74). Our own laboratory 
has showed that the persistent T-13910 allele represents a mean 92% of the expressed 
lactase mRNA in adults heterozygous for the C/T-13910 genotype (209). Previously, 
quantitation of allele-specific expression of lactase mRNA by a different method from 
ours in 15 lactase persistent children heterozygous for the same polymorphism 
G/A+593 in exon 1 of the lactase gene as analysed here, has shown equal expression in 
fetal samples and in the majority of those < 16 months (72).  However, the method 
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used in those cases was based on detection and quantitation of band intensity on 
autoradiographs, and it differs from our method in its accuracy. 
 
Recent studies assessing the functional role of the C/T-13910 polymorphism have 
demonstrated differential regulation of lactase promoter activity and binding capacity 
for the nuclear proteins in electromobility shift assay (EMSA) for the C-13910 and T-
13910 allele (96, 210). In EMSA, the T-13910 probe has been observed to interact more 
strongly and to a more abundant specific DNA/protein complex in comparison with 
the C-13910 probe (96, 210). In another current study (211), DNA affinity purification 
resulted in isolation of the Oct-1 transcription factor with glyceraldehyde-3-phosphate 
(GADPH) bound directly to the T-13910 variant site. Co-expression of Oct-1 binding 
the T-13910 enhancer region with HNF-1α (transcription factor with a binding site at the 
proximal lactase promoter) increased the effect of the T-13910 enhancer 133-fold over 
the proximal promoter activity. Oct-1 showed lower affinity to the C-13910 sequence, 
and the Oct-1/HNF-1α co-expression increased the expression less: 112-fold. Binding 
sites for other transcription factors with importance to intestinal gene expression, 
namely GATA-6, HNF4α, Fox/HNF3α and Cdx-2, were detected by DNase footprint 
and supershift analyses and characterized within the –13910 region. Mutations in any 
of above-mentioned transcription factor binding sites were observed to abolish the 
activity of the –13910 enhancer, demonstrating that the presence of all of the above 
mentioned binding sites is necessary for the –13910 region to possess enhancer 
activity. It was also established that the –13910 enhancer has a preference for the 
lactase promoter since it did not activate the MCM6 promoter in a transfection 
experiment (211).  
 
Based on these lines of evidence the –13910 region contains a strong transcriptional 
enhancer and substitution of cytosine to thymidine at –13910 site seems to have 
resulted in an increased activity of the enhancer and created a stronger Oct-1 binding 
site. At the time after weaning (mammals) or during childhood (humans) when lactase 
activity should decline in adult-type hypolactasia, the presence of Oct-1 at the T-13910 
enhancer may lead to either increased recruitment of activators of transcription or 
prevention of action of a repressor. This, in theory, compensates for the weak LCT 
promoter and ensures an active LCT gene throughout life. Lewinsky, et al (211), even 
speculate that since Oct-1 has been reported to recruit chromatin modifying co-factors 
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(256), it might be possible that the binding of Oct-1 to the T-13910 variant region in 
vivo would induce changes in the chromatin structure around the LCT gene, thus 
enhancing or silencing LCT expression. Despite these speculations, the detailed 
spatiotemporal pattern of specific protein-protein interactions between the –13910 
enhancer region and the lactase promoter in inducing lactase non-
persistence/persistence phenotypes during childhood still remains to be characterized. 
 
 
2. GENETIC TEST OF THE C/T-13910 VARIANT IN DIAGNOSIS OF ADULT-
TYPE HYPOLACTASIA 
 
The applicability of the genetic test of the C/T-13910 polymorphism in diagnosis of 
adult-type hypolactasia was assessed in the pediatric population (Study I) and in the 
adult population (Study IV). Our reference to the molecular diagnosis was the 
measurement of lactase activity and L/S ratio in the small intestinal mucosa (Study I) 
or in the large-scale study questionnaire-based (Study IV). Based on a questionnaire, 
the general attitudes towards the genetic test of adult-type hypolactasia and the 
probable effect of the test result on milk consumption were determined among 163 
children and their families (Study III). 
 
2.1 Genetic test of adult-type hypolactasia in children 
 
Genotyping of the C/T-13910 variant associated with lactase persistence/non-persistence 
status in > 300 children, with known disaccharidase activities, using a lactase activity 
of < 10U/g protein to be indicative of adult-type hypolactasia, the sensitivity of the 
genetic test (i.e. the probability of the C/C-13910 genotype in genetic test when the 
person has low lactase activity) was 93%. The specificity (i.e. the probability of 
genotype C/T-13910 or T/T-13910 being found in a genetic test when the person has high 
lactase activity) was 80%. However, adult-type hypolactasia is a trait that develops 
during childhood, thus the specificity of the genetic test in children > eight years of 
age was 97% and in those > 12 years of age 100%. The positive predictive value (i.e. 
the probability that a person with the genotype C/C-13910 has low lactase activity) had 
an increasing gradient, ranging from 10% in children < five years of age to 65% in the 
age group of six-11 years and 100% in children aged > 12 years.  
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2.2 Comparison of molecular diagnosis to LTT results in adults 
 
We asked the participants (n=1900) using questionnaires (study IV) about possible 
gastrointestinal symptoms and whether they had previous diagnosis of adult-type 
hypolactasia diagnosed by the lactose tolerance test (LTT). In this study with an 
extremely high response rate of 99%, among the participants with the C/C-13910 
genotype, 19% reported a positive LTT. It is of interest that of those with the C/T-13910 
genotype 10% (n=89) and those with the T/T-13910 genotype 14% (n=91) also reported 
being diagnosed as lactose malabsorbers by LTT. For seven of these in a total of 190 
subjects with genotypes C/T-13910 or T/T-13910 suggesting lactase persistence, the 
explanation for positive LTT could be a previously diagnosed celiac diasease. In 
addition, positive screening tests based on elevated level of transglutaminase 
antibodies in serum were observed in two other subjects. (Tikkakoski, submitted).  
 
2.3 Acceptance and implications of the genetic test  
 
We determined the genotypes for the C/T-13910 variant in a group of 172 children 
participating in a follow-up study on cow’s milk allergy and their controls (Study III) 
(222).  The acceptance of the genetic testing was very good as only two families 
refused to participate. The families of the children also filled in a questionnaire 
concerning gastrointestinal symptoms, including one question on the probable effect 
of the result of the genetic test on their milk consumption. Of all the families, 13% 
reported that the test result would have an effect on their milk consumption: among 
those with the C/C-13910 genotype, one third of the children reported a probable effect 
on their milk consumption. Of those children with the genotypes underlying lactase 





The genetic test of the C/T-13910 variant is in diagnostic use in several laboratories in 
Finland and Sweden. Several recent publications report technical advances providing 
more rapid and labor-saving means for performing the genetic test for the C/T-13910 
variant (215, 216, 257, 258). The C/T-13910 polymorphism, however, has been 
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suggested not to explain the lactase persistence/non-persistence trait in populations in 
Sub-Saharan Africa and therefore it has been stated that the genetic test of the C/T-
13910 polymorphism is premature and should not be used on African and other non-
northern European populations (218). 
 
Our results showed an excellent sensitivity and specificity for the genetic test in 
Finnish and Somali subjects by the age of 8-12 years. The genetic test of the C/T-13910 
variant has been compared with the results of breath hydrogen test (BHT) and lactose 
tolerance test (LTT) in some recent studies (213, 215, 216, 258). These studies have 
chiefly suggested a relatively good correlation with the indirect tests in Caucasian 
populations. In an Austrian study the sensitivity and specificity of the genetic test 
were 75% and 99%, respectively, compared with the BHT (213), and in Swedish 
subjects the genetic test and LTT showed concordant results in 94% of the subjects 
(216). In most cases, the discrepant results have been obtained in subjects with the 
heterozygous C/T-13910 genotype (213, 215, 216). However, studies comparing the 
C/T-13910 genotyping results to those of the indirect methods, with varying sensitivity 
and specificity (4), have their limitations. It should be kept in mind that the 
interpretation of the results obtained by indirect methods always depends on the cut-
off level chosen. Based on a Finnish study, the practice of carrying out lactose 
tolerance tests in Finnish health care centers varies widely with respect to the 
reference values as well as the follow-up of the symptoms (259).  Furthermore, the 
indirect test methods cannot rule out secondary lactase deficiency.  
 
It is obvious that the genetic test of adult-type hypolactasia is most useful in 
populations with relatively high prevalence of adult-type hypolactasia and in which 
the consumption of dairy products is common. In some Western populations, 
including those of Northern European countries, such as Sweden and Denmark, the 
prevalence of adult-type hypolactasia is low (50). However, in many of those 
populations there are today high numbers of immigrants from populations with 
extremely high prevalences of adult-type hypolactasia, such as the observed 100% 
prevalence of the C/C-13910 genotype in Somali children living in Finland (Study I). 
Thus, as the immigrants change their traditional diet to the lactose-containing diet of 
the new country and gastrointestinal symptoms appear (165), the diagnostic value of 
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the genetic test of adult-type hypolactasia can be assumed to become of more 
importance in these countries with mixed populations, too.  
 
Importantly, the genetic testing should be applied only after the age when the 
downregulation of lactase activity is complete, this being in Finnish children after 8-
12 years of age. There is concern that the molecular determination of the genetic 
predisposition to adult-type hypolactasia in children, at a time when lactase activity 
still is high or there are no symptoms of lactose intolerance, might lead to potentially 
harmful reduction in dairy product intake. Reduced calcium intake has been shown to 
contribute to reduced bone mineral density and osteoporosis (131). In general, the 
general recommendation is that predictive genetic testing of children should not be 
carried out unless there is an effective therapeutic intervention that can be offered 
(260, 261). In the case of lactose intolerance the treatment is easily performed by 
changes in diet, especially in countries such as Finland, which have a good 
availability of low-lactose dairy products as well as lactose-free milk, and with 
supplementation of calcium if needed. Furthermore, pharmaceutical preparations of 
lactase enzyme are available in most countries. However, one of the pitfalls of the 
genetic test of the C/T-13910 polymorphism is that the genotype C/C-13910, predictive of 
adult-type hypolactasia, does not tell either the age at which the symptoms will 
develop, or if any symptoms will develop or be experienced at all. Furthermore, the 
amount of lactose tolerated by the subjects with the C/C-13910 genotype is not known. 
Based on our results, one third of the children with the genotype C/C-13910 reported a 
probable effect on their milk consumption, whereas 10% of those with the C/T-13910 
and T/T-13910 genotypes reported that the test result was helpful in avoiding 
unnecessary restrictions in their consumption of lactose containing products (Study 
IV). 
 
In clinical practice, the role of the genetic test has been suggested to be limited to 
ruling out adult-type hypolactasia as a cause of intolerance symptoms (262). 
Furthermore, concern that the gastrointestinal symptoms of a patient with genotype 
predisposing to adult-type hypolactasia might be attributed merely to symptoms of 
lactose intolerance, delaying or preventing diagnosis of more serious causes of lactose 
intolerance due to secondary lactose intolerance, has been presented (262). Taken all 
this into consideration when interpreting the gene test results, it is still obvious that as 
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a first-stage screening method for adult-type hypolactasia, the advantages of the 
genetic test in comparison to the biochemical methods such as LTT and BHT are 
apparent, both for the patients and the laboratory personnel. The genotype of lactase 
persistence/non-persistence can be determined from one blood sample taken without 
fasting using semi-automated analysis, saving time and costs to health care services. 
Furthermore, the test is also more comfortable for the patients; it needs to be done 
only once in a lifetime and the interpretation of the test result is unequivocal (263). To 
summarize, the genetic test of adult-type hypolactasia has an excellent specificity and 
sensitivity in excluding primary hypolactasia as a cause of gastrointestinal symptoms 
in subjects of Caucasian origin. Further studies are needed to answer the question 
whether there exists other polymorphisms in populations where the T-13910 allele is 
underpresented or not yet studied (218).  
 
 
3. PREVALENCE OF GASTROINTESTINAL (GI) SYMPTOMS AND 
CONSUMPTION OF MILK PRODUCTS IN THE FINNISH POPULATION IN 
RELATION TO THE GENOTYPE OF ADULT-TYPE HYPOLACTASIA  
 
Gastrointestinal symptoms and consumption of milk products were assessed by a 
questionnaire-based approach in Finnish children (Studies I and III), and in Finnish 
adults (Study IV) with a more comprehensive questionnaire covering questions on the 
specific symptoms, their frequency and relation to meals, as well as consumption of 
particular dairy products, among others. In these studies we genotyped a total of 2118 
subjects completing the questionnaires for the C/T-13910 genotype, and thus were able 
to examine the reported milk related gastrointestinal symptoms and milk consumption 
based on the subjects’ molecularly defined lactase persistence/non-persistence status. 
 
3.1 Milk related symptoms and milk consumption in Finnish children 
 
In the first study (Study I), 22% of the Finnish children or their families completed a 
questionnaire about milk consumption and possible milk related symptoms. The 
response rate remained low, because we started the collection of the milk related data 
late during the study. Later on, 162 children with a history of cow’s milk allergy and 
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their controls filled in the questionnaires about milk consumption and specific 
gastrointestinal symptoms (Study III). The questionnaire used in this study was 
somewhat more comprehensive compared to the one used in Study I; thus the results 
of the questionnaires cannot be directly compared.  
 
Among participants in Study I, 35% of the children reported symptoms from milk 
products; however, no significant difference between symptoms reported by children 
with the C/C-13910 genotype and those with the genotypes C/T-13910 and T/T-13910 
associated with lactase persistence was observed. In Study III, abdominal symptoms 
during a one-week period were reported by 23% of the children in total: by one third 
of those with the C/C-13910 genotype and by 27% and 15% of those with the C/T-13910 
and T/T-13910 genotypes, respectively (p=0.05; C/C-13910 compared to T/T-13910 
genotype). Among the specific gastrointestinal symptoms, such as flatulence, loose 
stools, and constipation, experienced by the children, flatulence was the only 
symptom that differed according to the C/T-13910 genotype. Flatulence was reported by 
19% of those with C/C-13910 genotype compared to 12% and 5% of those with C/T-
13910 and T/T-13910 genotypes, respectively (p<0.04; C/C-13910 compared to T/T-13910 
genotype).  
 
A significant difference in milk drinking habits between the C/C-13910 and the non-
C/C-13910 genotype groups was observed in both Studies I and III. In Study I, 57% of 
the children with the C/C-13910 genotype associated with adult-type hypolactasia 
reported that they never drank milk (Table 6). In Study III, 44% of the children with 
the C/C-13910 genotype reported drinking < one dl of milk per day. In Study I, only 3% 
of those with the C/T-13910 or T/T-13910 genotypes reported never drinking milk 
(p<0.001 compared to those with C/C-13910 genotype) and in Study III, 20% of those 
with C/T-13910 and T/T-13910 genotypes reported drinking < one dl milk daily (p<0.02 
compared to those with C/C-13910 genotype). It should, however, be noted that in 21% 
of the children reporting drinking < one dl of milk in Study III, despite their lactase 
persistence/non-persistence genotype, cow’s milk allergy (CMA) was confirmed in a 
challenge test (each of them had a previous diagnosis of CMA). Notably, in Study III, 
93% of the children with C/C-13910 genotype, anyhow, reported consuming milk 
products; in 36% of these cases a low lactose containing diet was reported. No 
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correlation with the C/C-13910 genotype of adult-type hypolactasia to the presence of 
CMA was observed. 
 
 3.2 GI symptoms and milk consumption among Finnish adults 
 
During a three-month period in spring 2004, in total 99% of the adults participating in 
the study for genotyping the C/T-13910 variant in primary health care filled in the 
questionnaire. Among adults, 80% reported having experienced gastrointestinal (GI) 
symptoms during the previous three months, 84% of those with the C/C-13910 genotype 
and 79% and 78% of those with the C/T-13910 (p<0.05) and T/T-13910 (p<0.05) 
genotypes, respectively. Flatulence was the only symptom that the subjects with the 
genotype C/C-13910 reported more frequently compared to the subjects with the 
genotypes C/T-13910 (p=0.06) and T/T-13910 (p<0.05). Those with the C/C-13910 
genotype reported GI symptoms somewhat but not significantly more frequently 
during one week. It is of interest that among the participants of Study IV who 
attended primary health care because of gastrointestinal symptoms, the C/C-13910 
genotype was observed in 24% of the subjects, that is significantly more often than 
the observed 18% prevalence of the C/C-13910 genotype in the total study population 
(p<0.05).  
 
In Study IV, 82% of Finnish adults with genotype C/C-13910 suggestive of adult-type 
hypolactasia reported that they did not drink milk with meals. The figure is 
significantly higher than the approximately 60% of those with genotypes C/T-13910 and 
T/T-13910, respectively, who report not drinking milk with meals (p<0.0001) (Table 6). 
Among the subjects drinking milk with meals, those with the C/C-13910 genotype 
reported milk related symptoms somewhat but not significantly more often than the 
lactase persistent subjects. Only a minority of the subjects with the C/C-13910 genotype 
drank milk with meals and reported no symptoms from it. The estimation of the 
percentage of milk drinking but asymptomatic subjects with the C/C-13910 genotype in 
our study, however, is difficult since one third of the milk-drinking subjects with C/C-
13910 genotype did not answer the question on the symptoms related to milk. Cheese, 
on the other hand, was reported to cause symptoms for 17% of those with the C/C-
13910 genotype compared to 10% and 9% of those with the C/T-13910 and T/T-13910 
genotypes, respectively (p<0.05).  
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Table 6. Milk drinking by Finnish children and adults with regard to the C/T-13910 
genotype. The data for children not drinking milk is combined from Studies I 
(subjects reporting never drinking milk) and III (subjects reporting drinking < one dl 









































Our results (Study IV) showed that gastrointestinal (GI) symptoms are very common 
among the Finnish working age population. In a recent Finnish population-based 
study, 10% in an unselected cohort of young adults reported major GI-complaints, and 
more than third reported minor GI-complaints. Symptoms related to milk were 
reported by every fourth of the subjects; 6% of the subjects reported symptoms related 
to milk with low-lactose content, too (162). In a Finnish population-based study on 
school-aged children, 10% of the children reported GI symptoms related to milk; in 
8% of the children the symptoms were compatible with lactose intolerance (264). 
These figures are to some extent lower than in our studies on Finnish children; 
however it should be noted that our study population was somewhat pre-selected as 
the participants were either a subpopulation of children attending endoscopy because 
of GI complaints (Study I), or attending a follow-up study because of cow’s milk 
allergy and their controls (Study III). In any case, all these studies, demonstrate that 
unspecific GI complaints, especially those related to milk, are very common among 
Finnish children and adults.  
 
Finland has the highest consumption of milk products of any country (235). Study IV, 
though, demonstrated that only one third of Finnish adults reports drinking milk with 
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meals. In our study population 69% of young men reported drinking milk daily, this 
group being the most frequent milk drinkers. Among middle-aged women, only 26% 
reported drinking milk daily. Men, in general drank milk more than women, in all age 
groups studied (unpublished data). It is possible that this is due to factors simply 
related to a dislike of the taste of milk. Also, it can be speculated to be a combination 
of higher prevalence of gastrointestinal disorders in women, in general (158), and the 
common subjective feeling of milk often underlying them, as observed in Study IV. In 
Study I, not taking the C/T-13910 genotypes of the subjects into consideration, 55% of 
the Finnish children participating reported drinking > two dl of milk/day, 37% 
reported drinking one -two dl of milk/day and 8% not drinking milk at all. In Study 
III, among the eight - nine years old children with a previous diagnosis of cow’s milk 
allergy and their controls, 90% reported consuming milk products, although 24% 
reported drinking < 1 dl of milk/day. Thus, based on our studies < 10% of the Finnish 
children report drinking very little or no milk at all. To conclude, these data 
demonstrate that drinking milk with meals is common among Finnish children, but an 
increasing gradient in those excluding milk products is observed with increasing age 
among Finnish adults.  
 
A variety of abdominal symptoms are frequently attributed to lactose intolerance 
(265). In well-controlled studies, however, GI symptoms have been shown to occur 
independent of lactose intake (14). It has been observed that among those with self-
reported lactose intolerance only a proportion, in most studies < 70% of the subjects, 
are true lactose maldigesters (3, 162, 265-267). In our studies, GI symptoms were 
observed to occur frequently among both subjects with molecularly defined adult-type 
hypolactasia as well as the participants with lactase persistence. However, we 
observed that those adults with the genotype associated with adult-type hypolactasia 
used primary health care services significantly more often due to GI complaints than 
the lactase persistent subjects. In all the studies (I, III, and IV), subjects with the C/C-
13910 genotype of adult-type hypolactasia had self-restricted their milk consumption.  
However, some other component of milk than lactose, if any, seems to underlie the GI 





The amount of lactose tolerated in hypolactasia depends on several factors: the lactase 
activity in the small intestine, the composition of the colonic microbiota, the 
composition of the food in which lactose is consumed and the individual sensitivity to 
the stretching of the intestinal wall, among others (109). Adaptation to lactose 
consumption has been speculated to play some role as well (128, 268, 269). Taken 
these facts into consideration, it comes clear that it is very difficult to examine the 
level of lactase activity that would be needed in order to prevent lactose intolerance. 
We could not find any significant difference in symptoms from milk except for 
flatulence (Study III) between those children with the C/C-13910 genotype and those 
with genotypes suggesting lactase persistence. Secondly, we did not have the exact 
amounts of milk (lactose) consumed by the children available. Finally, our study 
population included children at various ages around the age at which lactase enzyme 
activity is downregulated and as only 28% of them were interviewed for the 
abdominal symptoms, the number of symptomatic children with the C/C-13910 
genotype and low lactase activity, unfortunately, was too small for any conclusions to 
be drawn for this complex issue.  
 
 
4. THE ROLE OF ADULT-TYPE HYPOLACTASIA IN THE 
DEVELOPMENT OF COLORECTAL CARCINOMA  
 
Diet has an important role in modification of the risk of colorectal cancer (CRC) 
(270). The role of dairy products in pathogenesis of CRC has been extensively 
studied, however, it has remained unclear (229, 233, 234, 236, 237, 239). Using the 
C/T-13910 variant associated with lactase persistence/non-persistence trait as a 
molecular marker, we conducted a large-scale study on a possible association between 




We observed that the C/C-13910 genotype associated with adult-type hypolactasia was 
found significantly more often among the Finnish subjects with colorectal carcinoma 
than among their controls (p<0.02), with an odds ratio (OR) of 1.40 (1.07-1.85) for 
having the genotype C/C-13910 and colorectal cancer, in comparison to the other 
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genotypes, C/T-13910 and T/T-13910. We had clinical data, including age at the time of 
diagnosis, tumour histology, stage and site of the tumour among others, for two of the 
three subpopulations of Finnish subjects with CRC available, in total for 92% of the 
cases. We, however, did not observe any significant differences when comparing the 
clinical characteristics of the patients with the C/C-13910 genotype and the ones with 
the C/T-13910 and T/T-13910 genotypes. 
 
Among the British subjects, the overall frequency of the C/C-13910 genotype was 9.0%, 
somewhat higher than the earlier reported frequency of adult-type hypolactasia in the 
United Kingdom (203, 271). Among the Spanish subjects of Catalonian origin, the 
total C/C-13910 genotype frequency was 34.6%. There was no difference in the lactase 
persistence/non-persistence genotype frequencies in British or Catalonian cases and 
controls. For the British and Spanish subjects, no clinical data was available. 
 
4.2 Discussion  
 
The consumption of dairy products has been suggested in several studies to be 
associated with a modest reduction in the risk of colorectal cancer (229, 233, 234). 
Finns have been observed to have the highest intake of milk and dairy products in the 
world, higher than that in the UK and Spanish populations (235). The dairy 
consumption of the subjects participating in this study, unfortunately, was not 
available. However, in our other studies on the Finnish population (Studies I, III, and 
IV) we observed that those with the C/C-13910 genotype associated with low lactase 
activity drink significantly less milk than those with genotypes C/T-13910 and T/T-13910 
and high lactase activity. It can be speculated that one reason affecting the elevated 
risk of colorectal cancer among those with the C/C-13910 genotype, could be their 
lower consumption of milk products shown to be protective against CRC. The slightly 
elevated risk observed only among the Finnish but not in the British and Spanish 
populations, on the other hand, could be a consequence of the risk being detected only 
in the populations where milk products have such an important role in the diet as in 
Finland, or where the differences in milk consumption among the C/T-13910 genotype 





Ingestion of lactose has been shown to alter the populations of the intestinal 
microbiota (272). In subjects with adult-type hypolactasia, lactose consumed has been 
suggested to act as a prebiotic (246, 273), i.e. as a food ingredient that is not digested, 
but that can indirectly stimulate growth and/or activity of lactic acid producing 
bacteria in the colon. In this sense, it would be assumed that subjects with adult-type 
hypolactasia consuming lactose regularly would be protected from colorectal cancer. 
Montalto, et al, have suggested inspired from our study that, in order to be able to 
assess the possible supplementary protective effect of lactose as a prebiotic, the 
population with adult-type hypolactasia should be stratified into two groups, the 
symptomatic and the asymptomatic subjects (274). Furthermore, Montalto et al, 
suggest that the risk in subjects consuming low lactose milk should be determined 
(274). 
 
As mentioned, the limitation of our study is the lack of the milk consumption data 
from the study participants. Without the data it is difficult to make any further 
conclusions on the harmfulness of lactose as such to those with the C/C-13910 genotype 
since the increased risk could also be caused by a lower intake of dairy products in 
comparison to those with C/T-13910 or T/T-13910 genotype. To summarize, this study is 
the first to have assessed the role of lactase activity in the development of colorectal 
cancer on this scale. The results of this study are new and exciting, but further studies 
are needed to confirm them. For this, a study assessing the role of consumption of 
milk products in subjects with the exact clinical course of colorectal cancer and 














CONCLUSIONS AND FUTURE ASPECTS 
 
 
The identification of the C/T-13910 polymorphism associated with lactase 
persistence/non-persistence trait in 2002 opened new avenues for basic and applied 
research into adult-type hypolactasia. The molecular marker facilitated studies on the 
timing and mechanism of the developmental downregulation of lactase activity. In 
this study we have demonstrated an excellent correlation between low lactase activity 
and the C/C-13910 genotype in all subjects > 12 years of age, irrespective of their 
ethnicity. Furthermore, we have demonstrated an increasing imbalance in the relative 
lactase mRNA expression from the C-13910 and T-13910 alleles in Finnish children 
beginning from five years of age, supporting causative role of this variant in adult-
type hypolactasia. The genetic test for adult-type hypolactasia has been introduced 
into routine diagnostics as an exclusion test for adult-type hypolactasia as a cause of 
abdominal symptoms. In this study the test showed a specificity of 100% in the 
Finnish children and adolescents > 12 years of age. 
 
Milk is an important component of the Northern European diet. In this work we, 
however, show that a significant percentage of Finnish children and adults report 
gastrointestinal symptoms related to milk. Comparison of milk consumption and milk 
related symptoms with regard to the C/T-13910 genotype of the participants revealed 
that Finnish children and adults with the C/C-13910 genotype associated with low 
lactase activity drink significantly less milk and report flatulence significantly more 
often than those with genotypes associated with lactase persistence. A proportion of 
subjects with the C/C-13910 genotype, nevertheless, reported drinking milk without 
experiencing any symptoms. In an association study an increased risk of colorectal 
cancer was observed among those with molecular diagnosis of adult-type 
hypolactasia. It, however, remained to be clarified whether the increased risk 
observed in the Finnish population could have been caused by lactose or decreased 
intake of dairy products in these subjects.  
 
Lactose intolerance is a complex phenotype. The genetic test of the C/T-13910 variant 
cannot exclude lactose intolerance; however, it can exclude primary adult-type 
hypolactasia underlying the symptoms. A predictive genetic test for adult-type 
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hypolactasia is of no value in children without symptoms from milk, at least as far as 
lactose has not been demonstrated to be harmful for those with the C/C-13910 genotype.  
In future, the role of the C/T-13910 SNP as the causing variant of adult-type 
hypolactasia in populations, including those of sub-Saharan Africa needs to be 
reconsidered. New insights into the molecular mechanisms underlying developmental 
downregulation of lactase activity have recently been obtained, however, the exact 
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